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Abstract
Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a multifunctional
protease implicated in cancer aggressiveness for its ability to promote proliferation,
migration, and invasion, particularly at low expression levels. Due to its multidomain
structure and cell signalling abilities, MT1-MMP may act as a key regulatory node
enhancing ATP production, which may confer further advantages in cell proliferation and
motility. Low levels of MT1-MMP that enhance cell growth/movement were examined
with respect to cell metabolism. Cells expressing different levels or forms of MT1-MMP
were cultured in media containing different metabolites to assess viability, proliferation,
and metabolic gene transcript levels. While cells with a cytoplasmic domain deletion in
MT1-MMP demonstrated more transcript level changes than cells that differed in MT1MMP levels, there were no metabolically relevant differences in metabolic gene
transcript levels, suggesting MT1-MMP does not modulate key metabolic pathways to
confer proliferative advantages.
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Summary for Lay Audience
The extracellular matrix (ECM) is a dynamic network of interconnected proteins
that provides structural support to cells. As cells move from one location to another
within an organism, the ECM must be remodeled to provide space for cells to move
through. Cell movement is essential for processes such as development and immune
function but is also a key component of various diseases such as cancer. Therefore, ECM
remodeling must be tightly controlled as dysregulation can lead to various disease states.
While there are many proteins capable of remodeling the ECM, matrix
metalloproteinases (MMPs) are arguably some of the most important. In my research, I
focused on membrane-type 1 matrix metalloproteinase (MT1-MMP) which is located on
the cell surface with parts of this protein extending both outside and inside the cell. Due
to this, MT1-MMP functions beyond ECM remodeling and is also capable of
communicating with the cell through various signalling pathways. MT1-MMP is
commonly abundant in cancer cells which characteristically rely on a modified cellular
metabolism (termed the Warburg Effect) to create ATP which further enhances cell
proliferation and movement. Therefore, the purpose of my research was to investigate if
MT1-MMP played a role in altering cell metabolism to resemble the Warburg Effect by
growing cells in different energy sources which included glucose, lactate, pyruvate, or
no-sugar. Here, while optimal low MT1-MMP expression levels enhanced proliferation
in glucose, MT1-MMP did not affect proliferation in other sugars. Further, MT1-MMP
did not affect the expression of several genes involved in the Warburg Effect suggesting
MT1-MMP does not modulate cancer cell metabolism at this level of regulation.
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Expanding our knowledge on the various roles of MT1-MMP is critical to understanding
how this protein functions to increase cancer severity and progression.
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1. Introduction
1.1 The extracellular matrix
The extracellular matrix (ECM) is a dynamic, non-cellular network of
macromolecules surrounding cells in tissues. Structurally, the ECM provides a physical
scaffold and support to cells, but it also serves as a reservoir for many signalling
molecules and can establish gradients of these molecules that in turn regulate bioactive
molecules spatially and temporally. Due to this, the ECM is far more than just structural
support for cells, it is also capable of affecting cell behaviour (Hynes, 2009). Cell-ECM
interactions allow cells to perceive their extracellular milieu and respond to
environmental cues. This becomes especially important for regulating cell differentiation,
proliferation, and migration, and therefore has large implications in development and
disease progression (Bonnans et al., 2014; Theocharis et al., 2016).
The ECM can be categorized into two forms: the interstitial matrix and the
basement membrane (BM). The interstitial matrix is mainly characterized by the presence
of collagen type I and resides in the mesodermal space connecting adjacent tissues. It
forms a porous 3-dimensional (3D) network where it plays a key role in providing
strength and structure to cells and tissues (Ingber, 2006). The BM is a thin sheet-like
structure separating the epithelium from the stroma. It is primarily composed of collagen
type IV and helps to maintain cell polarity as well as act as a barrier to prevent malignant
cells from invading into deeper tissues (Bourboulia and Stetler-Stevenson, 2010; Kalluri,
2003). During early morphogenesis, the BM defines tissue boundaries while also
exhibiting a level of plasticity that permits growth, movement, and cellular interactions
(Sekiguchi and Yamada, 2018).
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As a highly dynamic structure, the ECM is constantly being remodelled. ECM
dynamics can result from altered synthesis or degradation of ECM components, or
changes in architectural organization (Lu et al., 2011a). These changes are tightly
regulated by several redundant mechanisms to ensure proper development, and when
these mechanisms become dysregulated or mutated, it can lead to various congenital
defects and diseases such as cancer (Järveläinen et al., 2009; Lu et al., 2011a; Sekiguchi
and Yamada, 2018). Furthermore, as the ECM is remodelled, bioactive molecules that are
stored within the ECM can be released and change both cell-cell and cell-ECM
interactions (Yue, 2014). Survival of healthy cells rely on integrin-mediated attachment
to the ECM to elicit pro-survival and anti-apoptotic signals. Insufficient or defective cellECM interactions in healthy tissue causes the generation of reactive oxygen species
(ROS) and triggers a type of cell death called anoikis (Lu et al., 2015). Cancer cells are
characteristically resistant to the mechanisms that trigger anoikis and can therefore grow
without interacting with the ECM and thus can effectively evade this barrier to metastasis
(Bourboulia and Stetler-Stevenson, 2010).
While cell-ECM interactions are critical to normal cell survival, they are not
permanent since many physiological processes, such as cell movement during
development, require large, coordinated changes in ECM structure. For a cell to move,
the ECM must be degraded at the leading edge of a migrating cell to create a path for that
cell to move through. Components of the ECM are degraded by matrix-degrading
enzymes such as hyaluronidases, serine and threonine proteases, a disintegrin and
metalloproteinases (ADAMs), ADAM with thrombospondin motifs (ADAMTS) and
matrix metalloproteases (MMPs), as well as their inhibitors (tissue inhibitor of MMPs
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(TIMPs)) (Cox and Erler, 2011; Yue, 2014). While there are several matrix degrading
enzymes, MMPs are the most significant group of enzymes responsible for facilitating
ECM remodelling (Jabłońska-Trypuć et al., 2016).

1.2 Matrix metalloproteinases
MMPs, also called matrixins, are a group of zinc-dependent endopeptidases
responsible for selective degradation of ECM components (Bourboulia and StetlerStevenson, 2010; Nagase et al., 2006). There are currently 24 matrixin genes in humans
with one duplicated gene, and therefore 23 total MMPs. Several types of MMPs with
different substrate specificity exist, including collagenases, gelatinases, membranebound, stromelysins, and matrilysins. MMPs are most commonly divided into two groups
based on their subcellular location: membrane-type and secreted (Bourboulia and StetlerStevenson, 2010).
Typically, soluble MMPs have several functional domains including a signal
peptide, a propeptide domain, a catalytic domain, a linker peptide (hinge region), and a
hemopexin domain. Following removal of the signal peptide in the endoplasmic
reticulum (ER), MMPs are maintained in their inactive proMMP zymogen form by a
cysteine switch motif (PRCGXPD) within the propeptide domain. The catalytic domain
contains a zinc binding motif (HEXXHXXGXXH) in which three histidine residues bind
a Zn2+ ion. This zinc motif is necessary for the enzyme’s function and distinguishes
MMPs from all other proteinases (Cui et al., 2017). Most MMPs are soluble and secreted
into the ECM as inactive zymogens (proMMPs). To activate these zymogens, the
cysteine switch is cleaved, and the pro-domain is detached by other proteolytic enzymes
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(including other MMPs) which unblocks the catalytic site. Interestingly membrane-type
MMPs (MT-MMPs) are expressed at the cell membrane in an already active form as their
pro-domains are cleaved intracellularly within the Golgi via a furin dependent
mechanism, and thus are active before they reach the cell surface (Cui et al., 2017). In
addition to this pro-domain difference, MT-MMPs are also distinguished from their
soluble counterparts by a single-span transmembrane domain, anchoring the enzyme to
the cell membrane, and by a cytoplasmic tail. This cytoplasmic tail can confer several
non-proteolytic functions to MT-MMPs, including roles in cell signalling (Cui et al.,
2017; Jabłońska-Trypuć et al., 2016; Visse and Nagase, 2003).
When MMPs were initially discovered, it was believed that their primary role was
to cleave structural components of the ECM, thereby facilitating cell movement: roles
critical to proper development (Egeblad and Werb, 2002). However, it is now known that
MMPs are also able to cleave growth factor receptors, cell-adhesion molecules, and
activate growth factors and chemokines (Egeblad and Werb, 2002), thereby influencing
cellular functions independent of migration. Not only can MMPs change the environment
in which cells reside and cause the release of bioactive molecules through enzymatic
activity, but they can, particularly MT-MMPs, also interact with bioactive molecules
acting as a receptor, and thus have other important roles in modulating cell signalling and
behaviour, perhaps acting as nodes coordinating many pathways (Egeblad and Werb,
2002).
During normal development, MMP levels are elevated to facilitate the large-scale
cell movements that are necessary for proper morphogenesis, however their expression in
normal adult tissue is low (Freitas-Rodríguez et al., 2017). In adults, elevated expression
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levels are commonly associated with injury and repair, as well as diseases such as cancer.
MMPs have been implicated in cancer severity for over 40 years under the notion that
MMP-mediated ECM degradation leads to cell invasion and cancer metastasis
(Kessenbrock et al., 2010). MMPs have been reported to disrupt growth-promoting and
antigrowth signals within the tumour microenvironment therefore contributing to
uncontrolled cell proliferation, a common characteristic of many cancers. For example,
elevated activation of epidermal growth factor receptor (EGFR) in ovarian cancer results
in upregulation of MMP-9, which in turn degrades E-cadherin (Cowden Dahl et al.,
2008). Loss of E-cadherin disrupts many cellular functions including cell-cell adhesion
and differentiation. MMP-9 expression alone was reported to sufficiently cause Ecadherin loss contributing to ovarian cancer cell metastasis (Cowden Dahl et al., 2008).
However, given these enzymes do far more than just degrade physical barriers, their role
in diseases such as cancer is far more complex than that of just structural remodelling
associated with cell migration. MMPs have also been implicated in evasion of apoptosis,
another common cancer cell characteristic (Egeblad and Werb, 2002). Apoptosis can be
triggered by extracellular receptors such as Fas receptors which serve to activate
signalling cascades leading to controlled degradation of subcellular compartments and
nuclear DNA. MMP-7 can interfere with this signalling cascade by cleaving Fas therefore
allowing cells to evade normal programmed cell death and continue to grow
uncontrollably (Mitsiades et al., 2001). Finally, MMP-9 plays a role in increased
angiogenesis within the tumour microenvironment by increasing the bioavailability of
vascular endothelial growth factor (VEGF) which is a potent inducer of tumour
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angiogenesis (Bergers et al., 2000). Together, these roles highlight MMPs significant role
in cancer that is far more involved and complex than ECM degradation alone.
Many MMPs have overlapping, but diverse substrate specificity, and together
they can cleave virtually all ECM proteins (Sternlicht and Werb, 2001). Due to
redundancy in functionality, the exact function of individual MMPs is determined by
their differential expression patterns and their activation status. The functional
importance of such strict MMP control is highlighted by various pathological states when
MMP levels and activity are dysregulated (Sternlicht and Werb, 2001).

1.3 MMP regulation
ECM composition and dynamics have an integral role in modulating cell function
and behaviour. Due to the importance of this structure, MMP activity must be carefully
regulated. Usually, MMPs have low expression levels in healthy tissue, and therefore
their activity and location are tightly regulated (Sternlicht and Werb, 2001). Most MMPs
share common cis-elements in their promoter regions which results in strict control of
cell-specific expression, and because of this, MMPs are commonly co-expressed or corepressed in response to various stimuli. Within the promoter region, some key
transcription-binding sites involved in MMP regulation include the activator protein-1
(AP-1) site, polyomavirus enhancer-A binding protein-3 (PEA3) site, and the nuclear
factor kappa B (NF-"B) site (Fanjul-Fernández et al., 2010). Various cytokines, growth
factors, secondary messengers, and hormones that influence expression of MMPs do so
through complex interplay between these elements located throughout MMP promoters
(Benbow and Brinckerhoff, 1997; Chakraborti et al., 2003). For example, it has been
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reported that inflammatory cytokines increased the activation of MMP-1 through the
mitogen-activated protein kinase (MAPK) signalling pathway by increasing levels of AP1 proteins such as c-jun and c-fos (Fanjul-Fernández et al., 2010). Furthermore, many
MMP transcripts have sequences within their untranslated regions (UTRs) that are
binding sites for stabilizing or destabilizing proteins that determine mRNA stability. It
has been reported that levels of mRNA transcript can be protected against rapid
degradation by the binding of HuR stabilizing protein within one of the UTRs in MMP-9
(Fanjul-Fernández et al., 2010).
Post-translationally, in addition to being regulated by the presence of the propeptide domain, MMP activity is controlled by a group of secreted endogenous inhibitors
called TIMPs. Four TIMPs have been identified in vertebrates including TIMP-1, TIMP2, TIMP-3, and TIMP-4 (Visse and Nagase, 2003). While individual TIMPs vary in their
ability to inhibit various MMPs, collectively all TIMPs can inhibit all MMPs. The TIMP
molecule has a wedge-like shape and works to inhibit MMPs by inserting itself into the
active site in the catalytic domain similar to that of the substrate in a 1:1 stoichiometric
ratio (Nagase et al., 2006). Interestingly, while the N-terminal of TIMPs can interact with
the catalytic site of MMPs, the C-terminal region can interact with the pro forms of
MMP-2 and MMP-9 stabilizing the proenzyme in its inactive state. TIMP-2 is a unique
member as it interacts both with MMP-14, otherwise known as membrane-type 1 MMP
(MT1-MMP), and pro-MMP-2 to facilitate MMP-2 activation (Bourboulia and StetlerStevenson, 2010). Thus, depending on the stoichiometry, TIMP molecules can inhibit
MMP activity levels, or increase them. Accordingly, MMP proteolysis and TIMP
expression must be correctly balanced to maintain tissue homeostasis. When the
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MMP:TIMP ratio is unbalanced, it leads to aberrant MMP expression and commonly to
diseases such as cancer. Many cancers usually overexpress MMPs within the tumour
microenvironment and it is a widely accepted theory that MMPs drive the invasion and
metastasis of tumours (Kessenbrock et al., 2010).

1.4 Membrane-type 1 matrix metalloproteinase
MT1-MMP is a multifunctional transmembrane cell-surface MMP that has been
implicated in many diseases including cancer (Cerofolini et al., 2016). It is unique as it is
the only MMP that when knocked out in mice results in severe skeletal abnormalities and
ultimately death postnatally. MT1-MMP deficient mice also display craniofacial
abnormalities, arthritis, severe osteopenia, have soft tissue disorders, and impaired
angiogenesis before death (Holmbeck et al., 1999; Zhou et al., 2000). Therefore, due to
its indispensable role during development postnatally, as well as several human
pathologies, MT1-MMP is very well characterized.
Typical of MT-MMPs, MT1-MMP has a multidomain structure that consists of a
signal peptide, pro-peptide, catalytic domain, hinge region, hemopexin domain, stalk
region, transmembrane domain, and a cytoplasmic tail. Like other MMPs, it is
synthesized as an inactive zymogen, and like other MT-MMPs, MT1-MMP is activated
in the Golgi by cleavage at the Arg108-Arg-Lys-Arg motif in-between the pro-peptide
and the catalytic domain, via a furin dependent mechanism (Pahwa et al., 2014). Active
MT1-MMP is then transported to the cell surface with the catalytic domain being within
the pericellular space, and the cytoplasmic tail in the cytosol. As one of six MT-MMPs,
MT1-MMP is a collagenase with the widest substrate specificity being able to cleave
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both ECM and non-ECM components, some of which include collagen types I, II, and III,
fibronectin, laminins-1,-2,-4, and -5, fibrin, cluster of differentiation 44 (CD44), and
extracellular matrix metalloproteinase inducer (EMMPRIN) (Itoh, 2015). While MT1MMP is not able to cleave collagen type IV, it is the principal activator of MMP-2 which
is one of few enzymes capable of cleaving collagen type IV. To activate MMP-2, two
MT1-MMPs first form a homodimer through interaction between their hemopexin and
transmembrane domains. Then one MT1-MMP from the dimer is bound to the Nterminal domain of TIMP-2. The exposed C-terminal domain of this TIMP-2 then binds
proMMP-2 and brings it into proximity to the uninhibited MT1-MMP molecule within
the dimer complex, which can remove the pro-domain, thereby activating MMP-2 (Itoh,
2015; Will et al., 1996). Due to its ability to activate MMP-2 via the (MT1-MMP)2TIMP-2-proMMP-2 complex, MT1-MMP can effectively mediate cleavage of all major
types of collagens, making it a potent mediator of cell migration and invasion.
Collagens are the most abundant component of the ECM in tissues, therefore
posing a barrier to cell movement. For a cell to migrate, the ECM must be locally
degraded providing space for the cell to move through (Vicente-Manzanares, 2005).
MT1-MMP is a prominent collagenase driving cell movement due to its direct and
indirect ECM proteolysis capabilities, and by its ability to process other cell-surface
adhesion molecules. It has been shown to localize at the leading edge of migrating cells
to facilitate ECM degradation and proper formation of motility-associated structures such
as lamellipodia and invadopodia (Itoh, 2006). The leading-edge protrusion of a migrating
cell is driven by actin polymerization pushing the cell membrane forward and new
adhesions between the cell and the substrate (commonly the ECM) must form. At the
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same time, adhesions at the trailing edge of the cell must disassemble to allow the cell
body to move forward into the recently degraded space (Vicente-Manzanares, 2005). Not
only can MT1-MMP degrade the ECM itself, but ECM degradation can be amplified
through activation of MMP-2. MMP-2 activation by MT1-MMP is seen to be an
important step in cancer cell invasion as MMP-2 can cleave collagen type IV, a
prominent component of the basement membrane, whereas MT1-MMP cannot. The
(MT1-MMP)2-TIMP-2-proMMP-2 complex formation has been reported to be localized
in lamellipodia and upregulated by Rac family small GTPase 1 (Rac1) which is a GTPase
that stimulates the formation of lamellipodia. This suggests this localized complex
formation plays an important role in the leading edge of a migrating cell (Itoh et al.,
2001). Finally, CD44 is a cell surface adhesion receptor that is involved in cell-cell and
cell-matrix interactions (Senbanjo and Chellaiah, 2017). It has also been shown to
localize at the leading edge of migrating cells and is highly expressed in many cancers
(Senbanjo and Chellaiah, 2017). When MT1-MMP and CD44 are coexpressed in ZR-751 cells, cell motility significantly increased. However, there was no effect on cell motility
when CD44 or MT1-MMP was expressed alone indicating that CD44 shedding by MT1MMP enhances cell migration (Kajita et al., 2001). While it is clear MT1-MMP has a
prominent role in cell motility, its overexpression is not directly correlated with increased
migration and invasion. Overexpression of MT1-MMP has been implicated in disease
progression, however, migration and invasion has been shown to be most enhanced when
MT1-MMP levels were slightly but not excessively increased. For example, MCF7 breast
cancer cells with ~11-fold increase in MT1-MMP expression were more migratory and
invasive than MCF7 cells with a ~2500-fold increase (Cepeda et al., 2016). Therefore, as
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very high MT1-MMP levels do not directly correlate to cell motility, this suggests a nonproteolytic role may also impact cell movement.
MT1-MMPs role in cancer progression is oversimplified when looking solely at
proteolytic function as it can also exert effects on multiple cellular signalling pathways
independent of enzymatic substrate degradation. MT1-MMP has a short cytoplasmic tail
that is 20 amino acids in length that is involved in several cell signalling pathways, and
MT1-MMP localization and internalization, which consequently affects cell migration,
invasion, and stress resistance (Nakahara et al., 1997; Uekita et al., 2001; Uekita et al.,
2004). Upon deletion of the cytoplasmic domain, MT1-MMP localization to the leading
edge of migrating cells is disrupted thereby interfering with its ability to induce invasion
(Cepeda et al., 2017; Lehti et al., 2000). Proper localization of MT1-MMP at the
migration front is essential to its function to enhance cell motility. The amount of MT1MMP at the leading edge is also regulated by its removal from the cell surface via
internalization, recycling, and possible subsequent degradation. This internalization
process depends on tyrosine and di-leucine motifs located within the cytoplasmic tail, as
these are required for binding of adapter protein 2 (AP-2), a component of clathrin-coated
pits (Uekita et al., 2001).
As previously mentioned, MT1-MMP forms a complex with TIMP-2 to activate
pro-MMP-2. This MT1-MMP-TIMP-2 complex has also been shown to control cell
proliferation and migration through a non-proteolytic mechanism involving the
cytoplasmic tail of MT1-MMP. When TIMP-2 was added to the culture medium with
MCF7 cells expressing MT1-MMP, extracellular signal-regulated kinase (ERK)
activation was upregulated in a dose dependent effect. TIMP-2 addition to cells without
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MT1-MMP, or with mutated MT1-MMP did not have these effects. Additionally, ERK
activation by the MT1-MMP-TIMP-2 complex was dependent on the cytoplasmic tail,
and not related to extracellular domain catalytic function (D’Alessio et al., 2008). In
MCF7 cells, ERK activation has been associated with low MT1-MMP levels compared to
cells in which MT1-MMP expression is much higher, similar to the trend seen with
migration and invasion, both were also elevated by low but not high levels of MT1-MMP
(Cepeda et al., 2016). Sustained ERK signalling also plays an important role in focal
adhesion turnover, which is essential for cell migration as a cell would stay anchored to
its substrate without adhesion assembly and disassembly. One of several functions of
ERK signalling during adhesion turnover is the activation of m-calpain, an enzyme
required for adhesion turnover. In HT1080 cells treated with BB94, an inhibitor of MT1MMP, ERK signalling decreased resulting in reduced focal adhesion turnover and
therefore reduced cell migration (Takino et al., 2006). This suggests that sustained ERK
activation seen in focal adhesion turnover is dependent in-part upon non-proteolytic
functions of MT1-MMP.
In addition to MT1-MMPs non-proteolytic impact on cell migration, low levels of
overexpression of MT1-MMP in MCF7 cells has been shown to enhance cell viability in
certain stress situations such as growth in serum-free media, suggesting a role for MT1MMP in cell survival in the absence of typical growth signals (Cepeda et al., 2016).
Enhanced cell viability and migration go hand in hand as migrating cells likely move
away from native oxygen and energy sources: stressors that may reduce viability.
However, the mechanism behind this increase in cell survival within unfavourable new
environments is unknown. Cells may have to alter their metabolic pathways to ensure
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continued energy production during migration. It is unknown if the low MT1-MMP
expression level that optimizes both ERK signalling, cell migration, and cell invasion,
also optimizes energy production.

1.5 The Warburg Effect
One hallmark of malignant cells is the use of glycolysis to create ATP despite the
presence of sufficient oxygen (Courtnay et al., 2015). Glycolysis is a metabolic pathway
that breaks down one glucose into two molecules of pyruvate and produces energy in the
form of adenosine triphosphate (ATP). This metabolic shift in glucose metabolism in the
presence of oxygen away from oxidative phosphorylation (OXPHOS) was first
discovered by Otto Warburg (Warburg, 1925). Glycolysis can be utilized by all cells,
however in normal, non-proliferating cells, the end products of this pathway continue on
to be fully oxidized in the mitochondria via OXPHOS (Courtnay et al., 2015). In the first
few reactions of glycolysis, the pathway is primed with the input of 2 ATP which are
converted to adenosine diphosphate (ADP) as glucose is modified. This energy
investment eventually results in a production of 4 ATP, for a net gain of 2 ATP
molecules per unit of glucose. During glycolysis 2 molecules of pyruvate are also
produced from 1 glucose. Under aerobic conditions, glycolytic pyruvate is then converted
into acetyl-CoA via pyruvate dehydrogenase (PDH) where it can enter the tricarboxylic
acid (TCA) cycle which occurs within the mitochondrial matrix. In the TCA cycle,
acetyl-CoA is oxidized to ultimately produce 3 nicotinamide adenine dinucleotides
(NADH) and 1 flavin adenine dinucleotide (FADH2). These reducing equivalents fuel
OXPHOS by donating electrons to the electron transport chain (ETC) within the inner
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membrane of the mitochondria. This produces a high proton gradient within the
intermembrane space which powers ATP synthase to produce ATP as it moves protons
back into the matrix. This process is very efficient as it typically synthesizes 36 ATP
molecules from the complete oxidation of 1 glucose molecule. OXPHOS can only occur
under aerobic conditions as oxygen is required to accept electrons in the ETC (Courtnay
et al., 2015).
However, during hypoxic conditions, or in cancer cells utilizing the Warburg
effect, glycolytic pyruvate is converted into lactate rather than Acetyl-CoA in a reversible
reaction by lactate dehydrogenase (LDH) (Courtnay et al., 2015). LDH is a homo- or
heterotetramer molecule that is formed by the association of 2 different subunits: M and
H which are encoded by the LDHA and LDHB genes, respectively. These genes are
structurally distinct with LDHA preferentially converting pyruvate to lactate as it has a
higher affinity for pyruvate, while LDHB, having a higher affinity for lactate,
preferentially converts lactate to pyruvate (Urbańska and Orzechowski, 2019). Lactate
can then enter the Cori cycle where it is directed to the liver and converted back into
glucose (Courtnay et al., 2015). Despite the inefficiency in energy production, in the
presence of oxygen cancer cells predominately rely on glycolysis and convert glucose to
lactate to gain 2 ATP quickly, rather than completely oxidizing glucose in the
mitochondria to gain 36 ATP.
Glycolysis may be less efficient than OXPHOS, but glucose metabolism through
glycolysis can occur 10-100 times faster than through the mitochondria, making the
amount of ATP produced over a period of time comparable to that produced via
OXPHOS as long as glucose is not limiting (Liberti and Locasale, 2016; Shestov et al.,
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2014). This proposed reasoning for aerobic glycolysis supports the fact that cells within
the tumour microenvironment consume enormous amounts of glucose compared to
healthy tissue effectively outcompeting other cells, such as immune cells, for shared
energy resources. A lack of glucose supresses T cell function by impeding cytokine
production which is necessary for tumour clearance via the immune system further
driving cancer progression (Chang et al., 2015). Proliferating cells not only need ATP,
but also use glucose metabolism to generate biomass. Enhanced glucose consumption
increases production of glycolytic intermediates which can then be used as a carbon
sources to synthesize amino acids, nucleotides, lipids, and proteins; all important cellular
building blocks required for cell growth (Heiden et al., 2009; Lunt and Vander Heiden,
2011). Thus, inefficient production of ATP could be a possible trade-off to maintain high
fluxes through other anabolic pathways that emanate from glycolysis.
Another proposed mechanism for the Warburg effect is that elevated glycolysis
may produce an environment that is advantageous to cancer invasiveness. Lactate
production is increased therefore acidifying the surrounding microenvironment which
provides several benefits to cancer cells. One benefit is described by the acid-mediated
invasion hypothesis which suggests that the secretion of H+ ions (that occurs with lactate
secretion) by cancer cells into tumour-stroma interface promotes tissue remodelling such
as extracellular matrix degradation by proteinases as acidosis has been found to activate
pro-MMPs (Christensen and Shastri, 2015; Tjäderhane et al., 1998), thereby increasing
invasive capabilities (Estrella et al., 2013).
Interestingly, a link between changing metabolic pathways, lactate, and MMP
function is also seen with preimplantation mammalian embryos. Early blastocyst
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embryos rely on a glycolytic metabolism resembling that of rapidly dividing cancer cells,
however, as these embryonic stem cells begin to differentiate, they shift away from
glucose metabolism and predominately utilize lactate and pyruvate (Barbehenn et al.,
1974; Brown and Whittingham, 1991; Redel et al., 2012). This metabolic shift is not only
associated with changes in cellular pathways involving proliferation and differentiation,
but also with acidification and MMP activation which facilitates embryo implantation
into the uterus (Chen et al., 2007). Thus, a mechanism that links shifts in metabolism, cell
proliferation, and MMP function exists, and can be utilized by cells. Indeed, lactate has
previously been thought of as just a waste product, however more recently, lactate is now
being recognized as having several other critical roles including driving cancer
aggressiveness (Baltazar et al., 2020).
Lactate is produced exclusively from pyruvate via LDHA (Baltazar et al., 2020).
With cancer cells preferential metabolic pathway being glycolysis, lactate accumulates
within the tumour microenvironment reaching concentrations that can be up to 20-fold
higher (~40 mM) than healthy tissues (~1.5-3 mM) (Baltazar et al., 2020). In addition to
the acid-mediated invasion hypothesis, lactate can act as a metabolic substrate and a
signalling molecule: functions that ultimately contribute to the progression of cancer
(Baltazar er al., 2020). As a hydrophilic, weak acid, lactate requires transporters to
transport across membranes. These transporters are from the monocarboxylate transporter
(MCT) family consisting of MCTs 1-4 which have been found to be robustly expressed in
various human tumours (Baltazar et al., 2020). MCT1, otherwise known as solute carrier
family 16 member 1 (SLC16A1) and MCT4 (SLC16A3) have been strongly associated
with the Warburg effect (Granja et al., 2017). MCT1 is expressed in most tissues and is
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predominately associated with the uptake/extrusion of lactate, while MCT4 expression
has been found in highly glycolytic tissues and associated with the export of lactate.
Lactate is exported in glycolytic cells by MCT4 where it can then be taken up by
oxidative cells via MCT1 therefore saving glucose for glycolytic cells (Baltazar et al.,
2020). As a signalling molecule, lactate functions as an intracellular signaling mediator
during hypoxia inducible factor (HIF) and VEGF signaling, and an extracellular ligand
binding to G-protein-coupled-receptors (Baltazar et al., 2020). It can also elicit a range of
autocrine, paracrine, and endocrine responses (San-Millán and Brooks, 2017). These
numerous functions of lactate contribute to growth, proliferation and metastasis of cancer
cells (Baltazar et al., 2020).
While all these proposed functions of the Warburg effect are attractive models,
they all have their own limitations which is why the impact the Warburg effect has on
tumour growth and cancer progression remains largely controversial within the scientific
community (Liberti and Locasale, 2016). However, metastatic diseases, such as cancer,
consistently utilize glycolysis in the presence of oxygen suggesting that a glycolytic
metabolism may provide an advantage to migrating cells (Lu et al., 2015). A major
regulator of glycolytic activity in relation to oxygen levels is the transcription factor
hypoxia-inducible factor-1 (HIF-1).

1.6 HIF-1 and the Warburg effect
The transcription factor HIF-1 is a heterodimeric complex comprised of an !subunit and a %-subunit (Ziello et al., 2007). The !-subunit is regulated by oxygen
whereas the %-subunit is constitutively expressed. Normally in normoxic conditions, the
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oxygen-dependent degradation domain, located within the !-subunit, is hydroxylated by
prolyl hydroxylase domain (PHD) enzymes (Ziello et al., 2007). Hydroxylated residues
are then recognized von Hippel-Lindau tumour suppressor protein (pVHL) which leads to
ubiquitination and subsequent proteasomal degradation (Weidemann and Johnson, 2008).
Thus, under normal oxygen conditions, HIF-1! is degraded. Additionally, HIF-1! can be
inhibited by Factor-Inhibiting HIF-1 (FIH-1), which normally functions in normoxic
conditions. FIH-1 works to inhibit HIF-1 by hydroxylating an asparagine residue located
on HIF-1! preventing interaction with transcriptional co-activators p300 and CREB
binding protein (CPB) thereby inhibiting HIF-mediated gene transcription (Kiriakidis et
al., 2015). In hypoxic conditions however, hydroxylation is supressed allowing for
dimerization of ! and % subunits. The HIF-1 complex can then translocate into the
nucleus, interact with its co-activators, and bind to the hypoxia response element (HRE)
located in the promoter region of HIF-1 target genes thereby initiating their expression
(Greijer and Van Der Wall, 2004).
HIF-1 is involved in regulating many genes that favour a shift in energy
production towards glycolysis (Denko, 2008). Since OXPHOS cannot function without
oxygen, this makes sense during periods of hypoxia. HIF-1 activates transcription of
glycolytic enzymes, as well as glucose and lactate transporters (MCTs) to increase
glucose import and lactate export. It also downregulates OXPHOS by increasing
expression of pyruvate dehydrogenase kinase (PDK), a key player in determining
metabolic fate. PDK inhibits PDH, preventing conversion of pyruvate into acetyl-CoA,
thereby limiting entry of pyruvate into the TCA cycle and favouring glycolytic flux to
lactate (San-Millán and Brooks, 2017). HIF-1 also functions to increase expression of
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LDHA, further promoting conversion of pyruvate to lactate (Cairns et al., 2011). While
these functions normally occur during hypoxia, sustained HIF-1 activation during
normoxia is commonly seen in cancer, and HIFs overexpression is correlated with
increased cancer aggressiveness (Bárdos and Ashcroft, 2004). Aberrant HIF-1 activation
during normoxia can therefore sustain the Warburg effect exhibited by cancer cells,
however the mechanism behind constitutive HIF-1 activation that is commonly seen in
malignant cells is not yet fully understood (Gatenby and Gillies, 2004).

1.7 MT1-MMP mediated activation of HIF-1
Activation of HIF-1 during normoxia plays a pivotal role in shifting cancer cell
metabolism towards glycolysis by activating transcription of genes associated with a
glycolytic metabolism (Sakamoto et al., 2014; Semenza et al., 1994). One proposed
mechanism of this aberrant HIF-1 activity is mediated through MT1-MMP. The
cytoplasmic tail of MT1-MMP is needed to facilitate inhibition of FIH-1 by Mint3 within
the Golgi (Sakamoto and Seiki, 2010). Mint3 is a Munc18-1-interacting protein that,
unlike other mint isoforms, lacks the munc18-binding domain (Okamoto and Südhof,
1998), however it has a unique N-terminal domain capable of binding and inhibiting FIH1 (Sakamoto and Seiki, 2009). Mint3 is expressed in all tissues and localizes within the
Golgi (Okamoto and Südhof, 1998). The cytoplasmic tail of MT1-MMP binds FIH-1 and
colocalizes with Mint3, allowing Mint3 to inhibit FIH-1 (Figure 1). MT1-MMP has been
shown to be critical to the inhibition of FIH-1 by Mint3 as MT1-MMP knockout
abrogates FIH-1 localization to the Golgi (Sakamoto and Seiki, 2010). Originally
identified in macrophages, this mechanism of FIH-1 inhibition dependent on MT1-MMP
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Figure 1. Proposed mechanism of MT1-MMP mediated HIF-1! activation. One
proposed mechanism of MT1-MMPs involvement in mediating the Warburg effect is
through interaction with mint-3 and FIH-1. Within the Golgi, MT1-MMP colocalizes
with mint-3 therefore recruiting cytoplasmic FIH-1; an inhibitor of HIF-1! in the
presence of oxygen. Mint-3 is then able to inhibit FIH-1, thereby promoting HIF-1!
activation despite sufficient oxygen. HIF-1! can therefore form the HIF-1 complex and
activate transcription of genes involved in glycolysis, cell survival, and angiogenesis
ultimately promoting the Warburg effect. Based off Sakamoto et al., 2011.

21
and Mint3 has also been demonstrated in malignant tumour cells. For example, in MDAMB-231 cells, knockdown of Mint3 or MT1-MMP in normoxic conditions resulted in a
25 and 50% reduction, respectively, in lactate production indicating a reduced reliance on
aerobic glycolysis (Sakamoto et al., 2011). In MCF7 cells, which express Mint3 and FIH1 constituently, enhanced expression of MT1-MMP during normoxia increased the
production of lactate by 1.6-fold. This increase in aerobic glycolysis was dependent on
the presence of both Mint3 and MT1-MMPs cytoplasmic tail (Sakamoto et al., 2011).
MT1-MMP’s ability to indirectly activate HIF-1! is therefore a putative mechanism
contributing to the Warburg effect encouraging cell survival, growth, proliferation, and
migration.

1.8 MCF7 cells
MCF7 is a breast cancer cell line that has both estrogen and progesterone
receptors. As breast cancer cells without these receptors are typically more aggressive,
MCF7 cells are a naturally non-migratory and non-invasive cell line (Comşa et al., 2015;
Kumar and Aggarwal, 2016). Additionally, MCF7 cells are deficient in MT1-MMP and
thus represent a good model to further elucidate the function of MT1-MMP through
overexpression of this protein (Figueira et al., 2009). These cells are therefore utilized in
this study to understand the role MT1-MMP may play in modulating cell metabolism.

1.9 Hypothesis and objectives
Studying MT1-MMPs involvement in altering a cell’s metabolism will allow for a
more comprehensive understanding of this protein’s diverse functions. As cells migrate,
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they need to both locally degrade the ECM and respond to fluctuating energy demands.
By indirectly interacting with HIF-1!, MT1-MMP may help modulate cell migration by
optimizing ECM degradation in concert with energy production. While it is known that
MT1-MMP impacts cell movement, it is unclear why low (not high) levels of
overexpression optimizes migration, invasion, and viability (Cepeda et al., 2016).
I hypothesize that low (not high) levels of MT1-MMP that enhance cancer
cell migration, invasion, and viability, also enhance energy production—functions
that would be modulated through the cytoplasmic domain.
To test this hypothesis, I will utilize stable cell lines that were previously
generated from human MCF7 breast cancer cells that overexpress high levels of MT1MMP (C1), slightly overexpress low levels of MT1-MMP (C3) or express a mutated
form of MT1-MMP missing its cytoplasmic domain (ΔCD). In this study, these cells
were cultured in media containing different metabolic substrates to identify 1) cell
viability, 2) cell proliferation, and 3) changes in metabolic gene expression.
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2. Materials and methods
2.1 Cell culture conditions
The human adenocarcinoma breast cancer cell line MCF7 (ATCC® HTB-22™)
was generously donated by Dr. Postovit (Queens University). Three stable cell lines that
express significantly different levels, as well as different forms, of MT1-MMP were
previously generated by Dr. Cepeda and Jake Pelling (Cepeda et al., 2016; Cepeda et al.,
2017). To create these cell lines, MCF7 cells were selected following transfection with
full-length MT1-MMP cDNA constructs, or with a truncated (lacking cytoplasmic
domain) MT1-MMP cDNA construct. Cell populations were then isolated and assayed
for the level of MT1-MMP via qPCR and immunoblot analysis. The three cell lines
created were named C1, C3, and ΔCD. The C1 cell line expresses a ~2500-fold increase
in MT1-MMP expression compared to the MCF7 parental cells. The C3 cell line
expresses an ~11-fold increase in MT1-MMP expression compared to the MCF7 parental
cells. Finally, the ΔCD cell line expresses a truncated form of MT1-MMP that lacks its
cytoplasmic domain with a ~100-fold increase in MT1-MMP expression compared to the
MCF7 parental cells (Cepeda et al., 2016; Cepeda et al., 2017).
Control (normal media) cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM)/F-12 media (Gibco) containing 25 mM glucose and supplemented
with 10% fetal bovine serum (FBS), 100 IU/mL penicillin, and 100 µg/mL streptomycin,
and incubated at 37°C with 5% CO2. Cells were maintained under 80% confluency and
passaged accordingly using 0.25% trypsin-ethylenediamine tetraacetic acid (EDTA)
(Gibco). For experimental treatment, cells were cultured in the same conditions except
that the DMEM/F-12 media did not contain glucose, and instead was supplemented with
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7 mM sodium L-lactate (Sigma), or 7 mM sodium pyruvate (Sigma). Additionally, cells
were also cultured in “sugar-free” DMEM/F-12 media that did not contain glucose and
was not supplemented with another carbon source.

2.2 Cell proliferation and viability assays
To understand how MT1-MMP may affect a cell’s ability to grow and survive
using different metabolites, cell proliferation and viability were measured to generate
growth curves in cells cultured in either glucose, lactate, pyruvate, or “sugar-free” media.
Cells were seeded in triplicate at a density of 5x104 cells/ml in a 24-well plate. Each
growth curve was repeated twice to yield a total of 6 biological replicates. For each
growth curve, cells were plated in glucose and incubated for 24-hours irrespective of
treatment. Treatment media was added after 24-hours to ensure that (lack of) metabolites
did not affect cell adherence to the plate. Before counting adhered cells, media in each
well was removed, spun down and resuspended so that the number of cells detached from
the plate could also be counted, in addition to cells that were on the plate. Adhered cells
were counted after removal using a standard trypsin protocol. Cells were counted using a
DeNovix CellDrop™ cell counter in 0.4% Trypan Blue immediately after seeding and
again every 24-hours for 6 days. The percent of live cells (not stained by Trypan Blue)
compared to total cells was used as a measurement of cell viability. The number of
unstained cells was indicative of the live cells in culture on a given day and used to report
growth.
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2.3 RNA extraction and quantitative RT-PCR
Quantitative real-time PCR (qPCR) analysis was used to examine how glucose,
lactate, and pyruvate affect gene expression. Cells were seeded at a density of 5x104
cells/ml in a 24-well plate. RNA was collected from MCF7, C1, C3, and ΔCD cells from
3 wells each in the 24-well plate and then pooled 3 days after treated media was added (4
days after being plated) (Figure 2). Total RNA was extracted using TRIzol™ Reagent
(Invitrogen) according to the manufacturer’s instructions. RNA concentration and quality
were assessed using a NanoDrop2000 spectrophotometer (Thermo Fisher Scientific). 1
µg of RNA was then used to synthesize complementary DNA (cDNA) using the highcapacity cDNA reverse transcription kit (Applied Biosystems) according to the
manufacturer’s instructions. Initially, a TaqMan® gene expression plate (Cat. #4391524)
was used to measure transcript levels of 28 candidate metabolic genes selected from a
pool of 96 suggested targets, 3 internal controls, and 1 manufacturer’s control
(Supplementary Table 1), according to the manufacturer’s instructions. PCR reactions
were performed using the following conditions: 50°C for 2 minutes, 95°C for 20 seconds,
and then 40 repeated cycles of 95°C for 3 seconds and 60°C for 30 seconds using the
CFX96 Real-Time PCR Detection System (BioRad). Transcript levels were quantified
using the ΔΔCT method and displayed as fold change relative to MCF7 cells (cell-line
control) or cells cultured in glucose (metabolite control) (Livak and Schmittgen, 2001).
Of the 32 candidate genes, 10 genes with the largest fold changes were then selected to
be re-analyzed and statistically examined. TaqMan® single-tube gene expression assays
were purchased and then used to measure transcript levels of enolase 2 (ENO2), HIF-1!,
LDHA, malic enzyme 1 (ME1), phosphoenolpyruvate carboxykinase 2 (PCK2), PDK1,
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Figure 2. Protocol for RNA sample preparation. (a) Cells were passaged in triplicate.
(b) Cells were seeded at a density of 5x104 cells/mL in triplicate in glucose for 24 hours,
after which treatment media was added. (c) RNA was isolated from cells on day 4 of
growth (after day 3 of treatment). RNA from wells within 1 box were pooled, therefore
wells in 1 box constitute 1 sample. RNA was then used for subsequent qPCR analysis.
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PDK3, pyruvate dehydrogenase phosphatase 2 (PDP2), SLC16A1, SLC16A3, and
glucuronidase beta (GUSB) (as an internal control) (Table 1), according to the
manufacturer’s instructions. PCR reactions were performed using the following
conditions: 50°C for 2 minutes, 95°C for 20 seconds, and then 40 repeated cycles of 95°C
for 1 second, and 60°C for 20 seconds using the ViiA™ 7 real-time PCR system (Thermo
Fisher Scientific). Transcript levels were quantified by the ΔΔCT method vs GUSB and
displayed as fold change relative to MCF7 cells (cell-line control) or cells cultured in
glucose (metabolite control) (Livak and Schmittgen, 2001).
Although TaqMan probes and primers have high fidelity and have been optimized
for a given gene, I sought to confirm the changes in RNA levels in 3 candidate genes
between MCF7 cell lines cultured in glucose and pyruvate identified by the TaqMan
probes; these genes included ME1, PCK2, and PDK3, using 18S as an internal control.
cDNA was amplified using gene specific primers (Sequences provided in Table 2), and
qPCR quantified using SensiFAST SYBR (Bioline) and a CFX96 Real-Time PCR
Detection System (BioRad). qPCR was conducted at 95°C for 2 minutes, and then 40
repeated cycles of 95°C for 5 seconds, 60°C for 10 seconds, and 72°C for 20 seconds.
Transcript levels were quantified by the ΔΔCT method vs 18S and displayed as fold
change relative to glucose (Schmittgen and Livak, 2001). Amplicons were sent for
sequencing at the Robarts Genomics Facility to confirm PCR fidelity.

2.4 Statistical Analysis
Cell viability and proliferation assays were conducted with 6 biological replicates
and analyzed using a two-way ANOVA (factors: time, cell line) followed by a Tukey’s
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Table 1. Top 10 metabolic genes with the largest fold-changes from an initial screen of 32 genes and their respective function.
Gene
ENO2

HIF1!

LDHA

ME1

PCK2

Name
Enolase 2

Function
ENO2 is responsible for catalyzing the conversion of 2-phospho-D-glycerate to
phosphoenolpyruvate (PEP); the second last step in glycolysis. ENO2 is a neuron specific
enolase that has numerous roles in perpetuating a cancerous phenotype. It is commonly
overexpressed in tumours and contributes to accelerated glycolysis, increased cell survival,
and increased migration in cancer cells (Liu et al., 2018; Vizin and Kos, 2015).
Hypoxia inducible factor HIF1! is the alpha subunit of the heterodimeric transcription factor HIF-1 which
1!
functions as a master regulator to a cell’s physiological response to hypoxia. Normally
activated by hypoxia, HIF1! is commonly stabilized despite the presence of oxygen in
cancer cells leading to the promotion of glycolysis, and transcriptional activation of
many genes involved in cancer survival and progression (Bárdos and Ashcroft, 2004;
Huang et al., 2014; Semenza, 2009).
Lactate dehydrogenase
LDHA is responsible for converting pyruvate (the end product of glycolysis) to lactate
A
while regenerating NAD+ for earlier glycolytic reactions. Overexpression of LDHA has
been linked to increased cancer cell survival, proliferation, and metastasis. In addition, the
accumulation of lactate that occurs when pyruvate is directed away from mitochondrial
respiration suppresses the immune response. (Feng et al., 2018). Lactate also serves as an
oncometabolite with roles in both extracellular and intracellular signalling that encourage
cancer progression (Baltazar et al., 2020).
Malic enzyme
ME1 catalyzes the conversion of malate to pyruvate while reducing NADP+ to NADPH
linking the TCA cycle to glycolysis. Overexpression of ME1 has been linked to increased
tumorgenicity by interacting with p53 and promotes an increased reliance on aerobic
glycolysis (Liao et al., 2018). ME1 inhibition has been seen to reduce cancer cell growth by
disrupting metabolic and redox balance in cells (Murai et al., 2017).
Phosphoenolpyruvate
PCK2 is a mitochondrial gluconeogenesis enzyme catalyzing the rate limiting step
carboxykinase 2
converting oxaloacetate (OAA) to PEP. This isoform is commonly present in nongluconeogenic tissues including a variety of cancers. PCK2 expression provides an
advantage to cancer cells as it is able to generate glycolytic intermediates promoting
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PDK1

Pyruvate dehydrogenase
kinase 1

PDK3

Pyruvate dehydrogenase
kinase 3
Pyruvate dehydrogenase
phosphatase catalytic
subunit 2
Solute carrier family 16
member 1

PDP2
SLC16A1

SLC16A3

Solute carrier family 16
member 3

GUSB

Glucuronidase beta

glycolysis even under low-glucose conditions (Bluemel et al., 2021; Leithner et al., 2015;
Méndez-Lucas et al., 2014)
PDK1 is one of 4 PDK isoforms. PDKs are mitochondrial enzymes that function to inhibit
pyruvate dehydrogenase (PDH) thereby preventing the conversion of pyruvate into acetylCoA linking glycolysis to the TCA cycle. The action of PDK promotes a glycolytic
phenotype by redirecting pyruvate away from oxidative phosphorylation thereby promoting
tumour growth and metastasis (Liu and Yin, 2017; Sutendra and Michelakis, 2013).
PDK3 is one of 4 PDK isoforms. See PDK1 description for function.
PDP2 is responsible for the enzymatic resetting of PDH thereby promoting conversion of
pyruvate to acetyl-CoA fueling the TCA cycle and subsequent OXPHOS in the
mitochondria (Kono et al., 2018).
SLC16A1, otherwise known as monocarboxylate transporter 1 (MCT1), is part of the
SLC16 gene family that facilitate the proton-linked transport of monocarboxylates across
plasma membranes (Halestrap, 2013). MCT1 is strongly associated with the glycolytic
phenotype exhibited by cancer cells, specifically the uptake and export of lactate (Baltazar
et al., 2020).
SLC16A3, otherwise known as monocarboxylate transporter 4 (MCT4), is part of the
SLC16 gene family that facilitate the proton-linked transport of monocarboxylates across
plasma membranes (Halestrap, 2013). MCT4 is strongly associated with the glycolytic
phenotype exhibited by cancer cells, specifically the export of lactate (Baltazar et al., 2020).
GUSB is located in lysosomes where it is involved in the breakdown of
glycosaminoglycans (Naz et al., 2013)
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Table 2. Primer sequences used for qPCR validation
Gene
Forward (5’ à 3’)
ME1
ACCCTCACCTCAACAAGGACT

Reverse (5’ à 3’)
TGTTGAAGGAAGGTGGCAACA

Accession Number
NM_002395.6

PCK2

AGAGCACATGCTGATCCTGG

ATAGCCAGGTTGGTCTTGCC

NM_004563.4

PDK3

AGTGACCTAGGTGGTGGTGT

ACCAAATCCAGCCAAAGGGG

NM_001142386.3

18S

GCAATTATTCCCCATGAACG

GGGACTTAATCAACGCAAGC

M10098.1
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HSD test. qPCR analysis was conducted with 3 biological replicates with 2 technical
replicates each. Statistical analysis and graphing of data were performed using GraphPad
Prism Version 9.1.2 (225). PCR CT value results were analyzed using a two-way
ANOVA (factors: sugar, cell line) followed by a Tukey’s HSD test. Data are presented as
mean ± SEM. Levels of statistical significance are as follows: ****, p ≤ 0.0001; ***, p ≤
0.001; **, p ≤ 0.01; *, p ≤ 0.05.
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3. Results
I sought to investigate if MT1-MMP had a role in modulating sugar metabolism
by growing cell lines that differed in MT1-MMP expression or form in different sugars
and subsequently assaying cell numbers over a 6-day period in terms of their; 3.1,
viability (% live cells to total cells); and 3.2, growth (absolute cell number of live
adhered cells) and adhesion (live cell numbers recovered in removed media). I then
assessed 3.3 and 3.4, mRNA transcript levels in cell lines that was isolated after 3 days of
growth in different sugars (4 days total growth). Relative transcript level fold-changes of
each gene between cell lines within a sugar and between sugars within a cell line are
summarized in supplementary table 2 and 3, respectively. Average Ct values from PCR
analysis are summarized in supplementary table 4.

3.1 Cells with MT1-MMP lacking the cytoplasmic domain (ΔCD) had
reduced viability in glucose media, but not in other treatments
To determine if MT1-MMP expression levels or the presence of its cytoplasmic
domain had an impact on survivability of cells cultured in alternative or limiting energy
sources, cell viability was measured using the Trypan Blue exclusion test. Cells were
cultured in media containing either glucose, “no-sugar”, lactate, or pyruvate, and viability
(% live cells to total cells) was measured daily over a period of 6 days. All cells were
initially plated in glucose media, to ensure that altering metabolites did not interfere with
cell adherence, after which the glucose media was replaced with treatment media.
ΔCD cells, which express a truncated form of MT1-MMP, were significantly less
viable after 6 days in glucose media than MCF7 (p<0.05), C1 (p<0.0001), and C3
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(p<0.0001) cells which all express full-length constructs of MT1-MMP. Moreover, MT1MMP expression level did not affect cell viability as MCF7, C1, and C3 cells did not
differ in viability over the entire 6 days when cultured in glucose (Figure 3a). This
demonstrates that cells where MT1-MMP has a cytoplasmic tail has enhanced cell
viability in glucose conditions versus cells that lacked this domain.
In contrast, neither the presence of the cytoplasmic tail nor the level of MT1MMP expression affected cell viability in “sugar-free”, lactate, or pyruvate media.
MCF7, C1, C3, and ΔCD cells did not differ in their viability over the period of 6 days in
all treated conditions (Figure 3b, c, d). In addition, there is an unexpected decrease in cell
viability for all cell lines on day 3 in both “sugar-free” and lactate media, however this
decrease did not occur in glucose or pyruvate (Figure 3b, c).

3.2 Low levels of MT1-MMP, that enhance cell growth in glucose, do
not confer similar advantages in other metabolites
It has previously been reported that a slight increase in MT1-MMP expression
(the C3 cell line) was optimal for cell growth in glucose media both with and without
serum – though this past study used an indirect MTT metabolic assay as a proxy for cell
number (Cepeda et al., 2016). To assess whether these same MT1-MMP levels affected
cell growth when cells were given different carbon substrates to metabolize, MCF7 cell
lines (MCF7, C1, C3, and ΔCD) were cultured in glucose, “no-sugar”, lactate, or
pyruvate media, and live cells were counted daily over a period of 6 days to generate
growth curves. Cells were initially plated in glucose for 24 hours, after which the media
was replaced with the treatment. Therefore, day 2 of growth corresponds to 1 day in
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Figure 3. Cell viability between cell lines does not vary within different metabolites.
Viability (% live cells to total cells) of MCF7 cell lines incubated in media supplemented
with various metabolites. Cells viability was assessed using the Trypan Blue exclusion
test and measured daily for 6 days. Cells were plated in glucose for 24 hours after which
treatment media was added. The results of 6 biological replicates (3 technical replicates
each) are shown as mean ± SEM and were compared using a two-way ANOVA (factors:
time, cell line) and Tukey’s HSD test. * indicates significant differences on a given day;
see below.
(a) Cell viability in media containing 25mM glucose. ΔCD cells were less viable than
MCF7 (p<0.05), C1 (p<0.0001), and C3 (p<0.0001) cells by day 6. MCF7, C1, and C3
cells viability did not differ over the 6 days.
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(b) Cell viability in media not supplemented with a metabolite (“sugar-free”). Viability
did not statistically differ between cell lines.
(c) Cell viability in media containing 7mM lactate. Viability did not statistically differ
between cell lines.
(d) Cell viability in media containing 7mM pyruvate. Viability did not statistically differ
between cell lines.

36
treatment and so forth. Each day before cells were counted, media was removed, so that
cells detached from the plate could be counted in addition to adhered cells. The number
of cells in the removed media therefore represented the number of live cells in culture
that were not adhered to the plate, while the live adhered cells were counter after
trypsinization. Therefore, the number of cells is reported at each day for both live adhered
and live detached cells.

3.2.1 Cell proliferation in glucose
By day 4, cells in glucose media began showing differences in growth/number of
live adhered cells. On day 4 C3 cell numbers were significantly higher than C1
(p<0.0001) and ΔCD (p<0.0001) cells, but C3 cells were not different from MCF7 cells.
By day 5, C3 cell numbers were significantly higher than MCF7 cells (p<0.001) and even
more different than both C1 and ΔCD (p<0.0001) cells. All cell lines displayed
significantly different numbers of live cells by day 6 (p<0.0001) (Figure 4a). C3 cells
demonstrated the best growth in glucose media compared to all other cell lines as seen by
consistently higher and higher cell numbers day after day, while ΔCD cells grew the
worst (as previously reported in Cepeda et al., 2016 using an MTT assay). Interestingly,
the parental MCF7 cells grew significantly better than cells expressing excessive amounts
of MT1-MMP (C1) by day 6 (p<0.0001) (Figure 4a).
The number of live (not adhered) cells in the media that was removed (before
adhered cells were counted) did not significantly differ over the duration of the growth
curve in glucose (Figure 5a).

37

Figure 4. C3 cells are more proliferative in glucose, MCF7 cells are more
proliferative in other treatments. Number of live adhered MCF7 cell lines in media
supplemented with different metabolites was measured using a DeNovix CellDrop cell
counter daily for 6 days. Cells were plated in glucose for 24 hours after which treatment
media was added. The results of 6 biological replicates (3 technical replicates each) are
shown as mean ± SEM and were compared using a two-way ANOVA (factors: time, cell
line) and Tukey’s HSD test. * indicates significant differences on a given day; see below.
(a) Cell numbers in media containing 25mM glucose. On day 4, C3 cells grew better than
C1 and ΔCD (p<0.0001) cells, but did not statistically differ from MCF7 cells. MCF7
cell number was also greater than ΔCD (p<0.01). On day 5, C3 cell number was greater
than MCF7 (p<0.001), C1 (p<0.0001), and ΔCD (p<0.0001) cells. ΔCD cells also has
decreased cell number compared to MCF7 and C1 cells (p<0.0001). On day 6, all cell
lines statistically differed from one another (p<0.0001).
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(b) Cell proliferation in “sugar-free” media (media not supplemented with metabolite).
On day 4, MCF7 cells grew better than C1 (p<0.01), C3 (p<0.0001), and ΔCD
(p<0.0001) cells. C1 cells also had elevated cell number compared to ΔCD cells
(p<0.001). On day 5, MCF7 cells grew better than C1 (p<0.001), C3 (p<0.001), and ΔCD
(p<0.0001) cells. On day 6, cell lines did not statistically differ from one another.
(c) Cell proliferation in media containing 7mM lactate. On day 4, MCF7 cell number was
greater than all other cell lines (p<0.0001). On day 5, MCF7 cells grew better than C3
and ΔCD cells (p<0.0001), but did not statistically differ from C1. On day 6, MCF7 cell
number was increased compared to C1 (p<0.05), C3 (p<0.01), and ΔCD (p<0.01) cells.
(d) Cell proliferation in media containing 7 mM pyruvate. On day 4, MCF7 cells had
increased growth compared to ΔCD cells (p<0.05). On day 5, MCF7 cell number was
greater than all cell lines (p<0.0001). On day 6, MCF7 grew better than C1 and ΔCD
cells (p<0.001), but did not statistically differ from C3.
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Figure 5. Number of live detached cells increases after 2 days in treatment (3 days
total). The number of live cells in the media removed from the plate (detached cells) was
measured using a DeNovix CellDrop cell counter daily for 6 days. Cells were plated in
glucose for 24 hours after which treatment media was added. The results of 6 biological
replicates (3 technical replicates each) are shown as mean ± SEM and were compared
using a two-way ANOVA (factors: time, cell line) and Tukey’s HSD test. * indicates
significant differences on a given day; see below.
(a) Cell number in removed glucose media. The number of cells in the removed media
does not statistically differ between cell lines.
(b) Cell number in removed “sugar-free” media. On day 4, ΔCD detached cell number
was greater than MCF7 (p<0.0001), C1 (p<0.0001), and C3 (p<0.05). Detached cell
number of C3 cells was also greater than MCF7 (p<0.001). On day 5, ΔCD detached cell
number was greater than MCF7 (p<0.0001) and C1 (p<0.01). C3 cells also had increased
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detached cell number compared to MCF7 (p<0.01). On day 6, the number of detached
ΔCD cells was greater than MCF7 (p<0.0001) and C1 (p<0.001) and C3 cells also had
greater detached cells than MCF7 (p<0.05), but did not statistically differ from ΔCD or
C1 cells.
(c) Cell number in removed lactate media. By day 3, ΔCD cell number was increased
compared to MCF7 cells (p<0.05). On day 4, ΔCD detached cell number was increased
compared to MCF7 (p<0.0001), C1 (p<0.05), and C3 (p<0.01) cells. C1 also had a
greater detached cell number relative to MCF7 cells (p<0.01). On day 5, ΔCD cells
continued to be increased compared to all other cell lines (p<0.0001), however by day 6
was only greater than MCF7 cell number (p<0.01).
(d) Cell number in removed pyruvate media. On day 4, MCF7 cells had fewer cells in the
removed media compared to C3 (p<0.05) and ΔCD (p<0.01) cells. By day 5, MCF7 cell
number was decreased compared to C1 (p<0.0001), C3 (p<0.001), and ΔCD (p<0.0001)
cells. On day 6, MCF7 cell number increased greater than that of C3 (p<0.05), which had
the lowest cell number. ΔCD cell number was also greater than C3 cells (p<0.05) but did
not statistically differ from MCF7 or C1 cells.
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3.2.2 Cell proliferation in sugar-free
The low level of MT1-MMP expression in C3 cells that was optimal for cell
growth in glucose did not confer the same advantage in “sugar-free” media with respect
to live adhered cells. Indeed, by day 4 it was the parental MCF7 cells that grew
significantly better than C1 (p<0.01), C3 (p<0.0001), and ΔCD (p<0.0001) cells. At this
time ΔCD cells grew significantly less than C1 cells (p<0.001), however they did not
differ from C3 cells. By day 5, MCF7 continued to grow better than C1 (p<0.001), C3
(p<0.001), and ΔCD (p<0.0001), while C1, C3, and ΔCD cells did not differ from each
other. While MCF7 cells showed increased proliferation compared to other cell lines on
day 4 and 5, there were no significant differences between any of the cell lines by day 6
(Figure 4b).
The number of live detached cells in the media differed between cell lines by day
4. On day 4 there were significantly more live ΔCD cells detached from the plate than
MCF7 (p<0.0001), C1 (p<0.0001), and C3 (p<0.05) cells. C3 cells also had significantly
more live detached cells than MCF7 cells (p<0.001) which had the least cells in the
removed media compared to all other cell lines on day 4. Detached cells on day 5
followed a similar trend, with ΔCD cells having significantly more live cells detached
from the plate compared to MCF7 (p<0.0001) and C1 (p<0.01), but not from C3 cells. In
addition, on day 5, C3 cells had significantly more live detached cells than MCF7 cells
(p<0.01) which once again had the least cell number in the removed media. Finally,
detached cells on day 6 showed a similar trend to day 5, with ΔCD cells having
significantly more cells in the removed media than MCF7 (p<0.0001) and C1 (p<0.001).
C3 cells also had significantly more detached cells than MCF7 cells (p<0.05) (Figure 5b).
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3.2.3 Cell proliferation in lactate
Similar to “sugar-free” media, changes in MT1-MMP did not enhance numbers of
live adhered cells in lactate media. While cell lines did not differ from one another during
the first 3 days, by day 4 MCF7 cell numbers were significantly higher than all other cell
lines (p<0.0001). By day 5, while MCF7 were still growing the best, they only
significantly differed with C3 and ΔCD (p<0.0001), but not C1. At day 6, MCF7 cells
once again displayed higher numbers than all C1 (p<0.05), C3 (p<0.01), and ΔCD
(p<0.01) cells (Figure 4c). Thus, elevated expression levels of MT1-MMP do not provide
an advantage to cell proliferation in lactate.
Interestingly, counts of unattached cells in the removed media revealed cells may
still be growing even without substrate. By day 3 ΔCD cells had significantly more cells
in the removed media than MCF7 cells (p<0.05). ΔCD cells had the most live detached
cells compared to all other cell lines, despite growing poorly when adhered to the plate.
By day 4 ΔCD cells had significantly more detached cells than MCF7 (p<0.0001), C1
(p<0.05), and C3 (p<0.01) cells. C1 also had significantly more cells in the removed
media compared to MCF7 cells (p<0.01) which had the least number of cells. On day 5,
ΔCD cells continued to have significantly more live detached cells than all other cell
lines (p<0.0001). However, by day 6 the number of ΔCD cells in the removed media was
only significantly greater than MCF7 cells (p<0.01) (Figure 5c).

3.2.4 Cell proliferation in pyruvate
Lastly, numbers of adhered parental MCF7 cells showed an enhanced ability to
proliferate in pyruvate media. By day 4, MCF7 cells grew significantly better than ΔCD
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cells (p<0.05), and by day 5 showed significantly more growth than all cell lines
(p<0.0001). However, on day 6, MCF7 cell numbers did not differ from C3 cells, but
numbers were higher than both C1 and ΔCD cells (p<0.001) (Figure 4d).
Surprisingly, there were large numbers of viable cells seen in the removed
pyruvate media with all cell lines, numbers which only increased with time. On day 4,
MCF7 cells had the least number of live detached cells, differing significantly with C3
(p<0.05) and ΔCD (p<0.01) cells. Globally, while on day 5 MCF7 cells had the highest
number of adhered cells (Figure 4d), they still had significantly less viable detached cells
compared to C1 (p<0.0001), C3 (p<0.01), and ΔCD (p<0.0001) cells. Despite these low
numbers at day 5, by day 6 the number of MCF7 cells in the removed media significantly
increased compared to C3 cells (p<0.05), though they did not differ from C1 or ΔCD
cells. The number of detached ΔCD cells was also significantly greater than that of C3
cells at day 6 (p<0.05) (Figure 5d).
Taken together, these results indicated that although a slight increase in MT1MMP expression may be beneficial to increase cell numbers when glucose is abundant, it
does not provide a similar advantage in other metabolites or when energy source is
lacking.

3.3 MT1-MMP has a limited role in mediating RNA levels of metabolic
genes
While MT1-MMP did not confer a proliferative advantage to cells cultured in
“sugar-free”, lactate, or pyruvate media, the slight overexpression of MT1-MMP still
enhanced cell numbers in glucose. As well, C3 cells have previously been reported to be
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more migratory and invasive than other cell lines (Cepeda et al., 2016). Therefore, to
determine if this slight overexpression of MT1-MMP played a role in optimizing energy
production to confer these advantages, RNA levels of 32 metabolic genes available on a
pre-designed TaqMan plate were assessed when cell lines were cultured in either glucose,
lactate, or pyruvate media (Supplementary Table 1). Of these 32 genes, 10 genes with the
largest differences in RNA levels (either between cell lines, or between treatments), as
seen by PCR CT values, were selected to be statistically reanalyzed. These metabolic
genes are ENO2, HIF1!, LDHA, ME1, PCK2, PDK1, PDK3, PDP2, SLC16A1, SLC16A3
(Table 1). Once again, RNA levels were assessed when cell lines were cultured in either
glucose, lactate, or pyruvate media. Cells were plated in glucose for 24 hours, after which
treatment media was added. RNA was isolated after 3 days in treatment (4 days after
seeding). Firstly, to determine if expression of key genes involved in metabolism differed
between cell lines, RNA was extracted to compare transcript levels between cell lines
grown in the same sugar.

3.3.1 Metabolic transcript levels in glucose
With the exception of PDK3 levels, no other gene differed in mRNA levels
between MCF7, C1, C3, and ΔCD cell lines in glucose media. PDK3 RNA levels,
however, were significantly decreased in C3 cells compared to both MCF7 (p<0.01) and
C1 cells (p<0.05) (Figure 6a).
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Figure 6. Differences in RNA levels between cell lines (relative to MCF7 cells) within
one metabolite. RNA levels of different metabolic genes were assessed using qPCR
analysis. The results of 3 biological replicates (2 technical replicates each) are shown as
log2 transformed mean fold-change ± SEM and were compared using a two-way
ANOVA (factors: sugar, cell line) and Tukey’s HSD test: **, p<0.01; *, p<0.05.
(a) RNA levels in glucose media compared between cell lines. PDK3 RNA levels
decreased in C3 cells relative to MCF7 (p<0.01) and C1 (p<0.05) cells.
(b) RNA levels in lactate media compared between cell lines. LDHA RNA levels
decreased in ΔCD cells relative to MCF7 (p<0.05) and C1 (p<0.01) cells. PCK2 RNA
levels were increased in ΔCD cells relative to C1 cells (p<0.05). PDK1 RNA levels
decreased in ΔCD relative to MCF7 cells (p<0.05). SLC16A3 RNA levels increased in C3
cells relative to MCF7 cells (p<0.05).
(c) RNA levels in pyruvate media compared between cell lines. PDK1 RNA levels
decreased in ΔCD cells relative to MCF7 cells (p<0.05). SLC16A1 RNA levels decreased
in C3 cells relative to MCF7 cells (p<0.05).

47

3.3.2 Metabolic transcript levels in lactate
Contrary to glucose media, PDK3 RNA levels did not differ between cell lines in
lactate media, but PDK1 mRNA levels were reduced by 61% in ΔCD cells compared to
the parental MCF7 cells (p<0.05). ΔCD cells also showed a 79.4% reduction in LDHA
levels relative to MCF7 cells (p<0.05). Combined, these results suggest ΔCD cells may
utilize OXPHOS within the mitochondria in lactate. Many other genes associated with
glycolysis such as ENO2 and HIF1! did not differ in transcript levels between cell lines
in lactate, however, monocarboxylate transporter SLC16A3 levels did increase by 5.23fold in C3 cells compared to parental MCF7 cells (p<0.05) (Figure 6b). These differences
indicated cell lines differ in their ability to respond to lactate.

3.3.3 Metabolic transcript levels in pyruvate
Cell lines demonstrated unchanged transcript levels of the target genes between
each other in pyruvate media. The transcript level of genes did not differ between cell
lines apart from PDK1 and SLC16A1 levels which decreased in ΔCD cells and C3 cells
respectively (p<0.05) relative to MCF7 cells (Figure 6c). Overall, cell lines show few
differences in the levels of several key metabolic genes, which do not conclusively
demonstrate cells differ in their metabolic abilities.
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3.4 Cell lines alter mRNA levels of metabolic genes when cultured in
different metabolites
As differences between cell lines in response to various metabolites were
minimal, differences in transcript levels within cell lines grown in different metabolites
were then examined.

3.4.1 Metabolic transcript levels in MCF7 cells
In the presence of pyruvate, MCF7 cells decreased RNA levels of LDHA by 73%
(p<0.05) while increasing PCK2 RNA levels 5-fold (p<0.01) relative to glucose
conditions, however mRNA levels of these genes did not differ in lactate media. PDK3
mRNA levels decreased in both lactate and pyruvate media, but saw a more significant
decreased in pyruvate (p<0.0001) than lactate (p<0.05) compared to glucose. In addition,
PDK1 mRNA level also decreased slightly in both metabolites, however, did not
significantly differ from glucose. Conversely, ME1 mRNA levels in MCF7 cells
increased 21-fold in lactate (p<0.0001) and 9.9-fold in pyruvate (p<0.0001) relative to
glucose (Figure 7a).

3.4.2 Metabolic transcript levels in C1 cells
C1 cells saw similar changes in mRNA levels to MCF7 cells. LDHA mRNA level
also decreased in pyruvate media by 82.1% (p<0.01) relative to glucose mRNA levels.
PDK3 mRNA levels also saw a 76% decrease in lactate and pyruvate media (p<0.001)
compared to glucose. Interestingly, despite decreased transcript levels of glycolytic
proteins LDHA and PDK3, ME1 mRNA levels in C1 cells increased 9-fold and 6.2-fold
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Figure 7. Differences in RNA levels between metabolites (relative to glucose) within
an individual cell line. RNA levels of different metabolic genes were assessed using
qPCR analysis. The results of 3 biological replicates (2 technical replicates each) are
shown as log2 transformed mean fold-change ± SEM and were compared using a twoway ANOVA (factors: sugar, cell line) and Tukey’s HSD test: ****, p<0.0001; ***,
p<0.001; **, p<0.01; *, p<0.05.

Lactate

Pyruvate

50
(a) RNA levels in MCF7 cells compared between metabolites. LDHA RNA levels
decreased in pyruvate media relative to glucose (p<0.05) and lactate (p<0.01) media.
ME1 RNA levels increased in both lactate and pyruvate media relative to glucose media
(p<0.0001). PCK2 RNA levels increased in pyruvate media relative to glucose (p<0.01).
PDK3 RNA levels decreased in both lactate (p<0.05) and pyruvate (p<0.0001) media
compared to that in glucose.
(b) RNA levels in C1 cells compared between metabolites. ENO2 RNA levels decreased
in pyruvate media relative to lactate (p<0.05). LDHA RNA levels were decreased in
pyruvate media relative to glucose and lactate (p<0.01). ME1 RNA levels increased in
lactate and pyruvate media relative to glucose (p<0.001). PDK3 RNA levels decreased in
lactate and pyruvate media relative to glucose (p<0.001).
(c) RNA levels in C3 cells compared between metabolites. HIF1! RNA levels increased
in pyruvate media relative to glucose media (p<0.05). ME1 RNA levels increased in both
lactate and pyruvate media relative to glucose (p<0.001). PCK2 RNA levels increased in
lactate and pyruvate media relative to glucose media (p<0.01). PDK3 RNA levels
decreased in pyruvate media relative to glucose (p<0.05). PDP2 RNA levels increased in
pyruvate media relative to glucose (p<0.05).
(d) RNA levels in ΔCD cells compared between metabolites. ENO2 RNA levels
decreased in lactate (p<0.05) and pyruvate (p<0.01) media relative to glucose. LDHA
RNA levels decreased in both lactate (p<0.01) and pyruvate (p<0.001) media relative to
glucose media. ME1 RNA levels increased in lactate (p<0.01) and pyruvate (p<0.05)
media compared to glucose. PCK2 RNA levels also increased in lactate (p<0.001) and
pyruvate (p<0.05) media relative to glucose. PDK1 RNA levels decreased in lactate
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(p<0.01) and pyruvate (p<0.001) media relative to glucose while PDK3 RNA levels only
decreased in pyruvate media relative to glucose (p<0.01). PDP2 RNA levels were
increased in lactate media relative to glucose (p<0.05). SLC16A1 RNA levels increased in
lactate media relative to both glucose (p<0.01) and pyruvate (p<0.05) media.
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in lactate and pyruvate respectively (p<0.001) compared to mRNA levels in glucose
(Figure 7b).

3.4.3 Metabolic transcript levels in C3 cells
Of all cell lines, HIF1! mRNA levels were only elevated significantly in C3 cells,
increasing by 6.9-fold in pyruvate media (p<0.05) relative to that in glucose. While
HIF1! transcript levels were also increased 2.8-fold in lactate, this level was not
significantly different from glucose. In addition, C3 cells also increased mRNA levels of
ME1 (p<0.001) and PCK2 (p<0.01) in response to treatment with either lactate or
pyruvate. HIF1!, ME1, and PCK2 upregulation has been seen in many cancers utilizing
the Warburg effect, however C3 cells also decreased PDK3 mRNA levels by 57.2%
(p<0.05) and increased PDP2 mRNA levels 4.6-fold (p<0.05) in pyruvate media relative
to glucose suggesting OXPHOS is not inactive (Figure 7c).

3.4.4 Metabolic transcript levels in ΔCD cells
Finally, ΔCD cells displayed several opposing differences in glycolytic transcript
levels displaying the most significant changes in RNA levels of all the cell lines. Similar
to the other cell lines, ΔCD cells also increased ME1 mRNA levels in response to lactate
(p<0.01) and pyruvate (p<0.05) relative to that in glucose media. PCK2 mRNA levels
followed a similar trend and were upregulated 10.6-fold in lactate (p<0.001) and 4-fold in
pyruvate (p<0.05) compared to glucose. In opposition to other cell lines, ENO2 mRNA
levels in ΔCD cells decreased in lactate (p<0.05) and in pyruvate (p<0.01) compared to
glucose. LDHA transcript levels also significantly decreased by 82.4% in response to
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lactate (p<0.01) and by 90% in response to pyruvate (p<0.001). Interestingly, ΔCD cells
were the only cell line in which both PDK1 and PDK3 mRNA levels decreased. PDK1
transcript levels decreased to 35% in lactate (p<0.01) and to 18.8% in pyruvate (p<0.001)
relative to transcript levels in glucose. PDK3 mRNA levels decreased in both lactate and
pyruvate but was only significantly less in pyruvate which decreased by 70% (p<0.01) in
comparison to glucose. Further, PDP2 mRNA levels were significantly increased in
lactate (p<0.05), but levels did not differ from glucose in pyruvate. Lactate also resulted
in 5.6-fold increase in SLC16A1 mRNA levels (p<0.01) (Figure 7d).
Overall, these results suggest the cell lines that differ in MT1-MMP differ only
slightly in their response to various metabolites. In particular, ΔCD cells had the most
significant differences in mRNA levels between metabolites indicating the cytoplasmic
tail may have a role in metabolic signalling.

3.5 Confirmation of mRNA fold changes
To confirm mRNA fold changes, another method of PCR was used to measure
transcript levels of ME1, PCK2, and PDK3. mRNA levels of these genes were compared
between MCF7 cells in glucose and pyruvate. Similar increases in fold changes were seen
with ME1 and PCK2 using the different (SYBR green) method of PCR, however there
was no significant change in PDK3 mRNA levels which decreased when assayed using
TaqMan probes. DNA sequencing of the amplicons confirmed gene identities (data not
shown).
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4. Discussion
This work aimed to investigate the role of MT1-MMP in cell metabolism by
analyzing cell viability, growth, and metabolic gene expression following incubation in
media supplemented in different carbon sources. This study used cell lines, previously
generated from MCF7 breast cancer cells, that excessively overexpress MT1-MMP (C1),
slightly overexpress MT1-MMP (C3), or express a form of MT1-MMP that lacks the
cytoplasmic domain (ΔCD) (Cepeda et al., 2016; Cepeda et al., 2017). Following
incubation in media supplemented with either glucose, lactate, pyruvate, or without a
carbon source, cell viability, growth, and metabolic gene expression were assessed.
Based on previous studies that demonstrated differences in cellular responses to stress, I
hypothesized that the cytoplasmic tail and slight MT1-MMP overexpression (C3 cell
line) are needed to optimize energy production which in turn would result in increased
viability, growth, and glycolytic gene expression in media containing different carbon
sources.

4.1 Absence of the cytoplasmic tail of MT1-MMP reduced the viability
of adhered MT1-MMP containing MCF7 cells in glucose
A common characteristic of cancer cells is their ability to survive in unfavourable
environments (Hanahan and Weinberg, 2011). There are many cellular processes that
when combined can contribute to elevated cell survival, one of particular importance
being the ability to create ATP. The ability to produce sufficient energy ultimately
dictates cell survival especially when nutrient supply fluctuates. Cancer cells
predominately utilize aerobic glycolysis to meet their energy needs, a phenomenon
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termed the Warburg effect. A reliance on aerobic glycolysis commonly results in
accelerated depletion of glucose and accumulation of glycolytic end products pyruvate
and lactate, by-products which can then be beneficial as they can also be used as
metabolic fuels in other pathways (Baltazar et al., 2020). Increased MT1-MMP levels
have previously been reported to play a role in enhancing survivability of hepatocellular
carcinoma cells when they detached from a substrate and migrated to a new location (Ip
et al., 2005). However, it is unclear if this survival involved optimizing energy
metabolism, especially as such cell movement in vivo may involve access to different
metabolites. In this study, as a first step towards evaluating the response of MCF7 cell
lines to growth in media supplemented with different carbon sources, cell viability was
assessed by comparing the number of live cells to dead cells that were adhered to the
plate. MT1-MMP increases survival in glucose after 6 days (Figure 3a), a role that
involves the cytoplasmic tail as cells lacking this domain (ΔCD cells) were the least
viable compared to all cell lines expressing full-length MT1-MMP. These differences
were only seen after 6 days of growth, with no differences being seen in the preceding
days (Figure 3a). Not only were ΔCD cells least viable, they also had the least number of
live adhered cells in glucose further implicating the cytoplasmic tail in survivability when
glucose is abundant (Figure 4a). However, there was no difference in viability
measurements between MCF7 cell lines expressing different levels or forms of MT1MMP in lactate, pyruvate, or “sugar-free” media, likely indicating MT1-MMP may not
be a central mediator of cell viability in these nutrient conditions (Figure 3b, c, d).
A previous study by Cepeda et al. (2017) using the same ΔCD cell line similarly
demonstrated that the cytoplasmic tail was necessary to mediate cell viability, in both
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serum and serum-free conditions. Cells expressing full-length MT1-MMP constructs had
a greater number of viable cells than those with a mutated or absent cytoplasmic domain,
and this difference was most pronounced when cells were stressed without serum. In full
serum, the cytoplasmic tail was still advantageous to cell survival, however, not until
after several days, after a time at which growth factors in the media were largely depleted
(Cepeda et al., 2017). While the need for the cytoplasmic domain of MT1-MMP to aid in
cell viability after 6 days in glucose and serum was confirmed in this study, suggesting
this domain is involved in upregulating cell survival mechanisms during periods of stress
such as in the absence of adequate growth factors (Cepeda et al., 2017), the absence of
this domain did not impact viability under the stress of glucose removal. Given that the
cytoplasmic tail of MT1-MMP has been reported to be involved in ERK and HIF-1
signalling (Gingras et al., 2001; Sakamoto and Seiki, 2010; Sakamoto et al., 2011),
pathways with roles critical to cell survival (Chen and Sang, 2016; Gingras et al., 2001),
this suggests that while cells expressing full-length MT1-MMP constructs are more
viable in glucose than cells expressing MT1-MMP lacking a cytoplasmic domain, they
may not use the same signalling mechanisms when glucose is absent – regardless of the
state of MT1-MMP in the cell.

4.2 Low MT1-MMP levels provide a proliferative advantage to adhered
MT1-MMP containing MCF7 cells in glucose
Having looked at viability (live/dead cell numbers) of MCF7 cell lines, I then
sought to assay cell proliferation in various carbon sources by counting the number of
live cells adhered to the plate. Uncontrolled cell proliferation is characteristic of cancer
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cells and MT1-MMP overexpression has been correlated to not only increased
proliferative capabilities, but also increased migratory and invasion potential leading to
enhanced cancer aggressiveness and poor prognosis (Hotary et al., 2003; Knapinska and
Fields, 2019). In this study however, cells with a slight overexpression of MT1-MMP
(C3) were more proliferative than cells excessively overexpressing MT1-MMP (C1)
when cultured in glucose conditions (Figure 4a). These findings are in agreeance with
previous work that also demonstrates low levels of MT1-MMP, rather than high, increase
proliferation, migration, and invasion (Cepeda et al., 2016). This finding (that low not
high levels of MT1-MMP are a greater impact on cancer progression) is also supported
by another study that reported the metastatic ability of human cancer cells was not
increased by MT1-MMP overexpression alone (Yamamoto et al., 2008). Together these
findings indicate that MT1-MMP has other complex roles involved in mediating cell
proliferation, migration, and invasion that may be hindered by excessive amounts of the
protein.

4.2.1 MT1-MMP and intracellular signalling
MT1-MMP has been implicated in several signalling cascades that are involved in
modulating cell proliferation such as the ERK signalling pathway (Sun et al., 2015).
Activation of the ERK signalling cascade by MT1-MMP can occur through interaction
with TIMP-2 in which TIMP-2 binds MT1-MMP to induce ERK phosphorylation via the
Ras-Raf-1-MEK1/2 pathway. This method of ERK activation occurs independent of
proteolytic activity and requires the cytoplasmic tail as cells devoid of MT1-MMP
proteolytic activity activated ERK signalling whereas cells expressing MT1-MMP
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lacking a cytoplasmic domain did not (D’Alessio et al., 2008). Additionally, a study by
Cepeda et al. (2016) demonstrated that MCF7 cells expressing high levels of MT1-MMP
(C1 cells) had decreased ERK activation compared to cells expressing lower levels (C3
cells) suggesting this pathway is optimally induced by low levels of MT1-MMP rather
than high. Since ERK signalling has a prominent role in triggering numerous
transcriptional changes that support cell proliferation (Lavoie et al., 2020), it may
therefore be contributing to the accelerated proliferation demonstrated by C3 cells in
glucose. The increased growth of C3 cells versus that of parental MCF7 cells further
demonstrates that optimal, though low, levels of MT1-MMP appear to aid cancer cells in
their expansion via mechanisms independent of the proteolytic activity of MT1-MMP
(Cepeda et al., 2016).
In addition to ERK signalling, another mechanism in which MT1-MMP may
induce cell proliferation and survival under a number of conditions is through the Akt
pathway. Activation of this pathway occurs via TIMP-2 binding MT1-MMPs catalytic
domain and is proteolysis-independent (Valacca et al., 2015). As Akt activation is not
unlike that of MT1-MMP mediated ERK activation, it is possible that lower levels of
MT1-MMP are more effective at inducing signalling as both involve TIMP binding. As
TIMP-2 is also an inhibitor of MT1-MMP, it is likely that under some stoichiometries
(high MT1-MMP levels) there is degradation of the ECM, while in others, such as with
low MT1-MMP levels, there is TIMP inhibition of degradation, and optimal signalling.
While Akt is a serine/threonine kinase that plays a key role in phosphoinositide 3kinase (PI3-K) signalling which is central to both cell survival and proliferation in
addition to exerting anti-apoptotic properties (Grandage et al., 2005), Akt has also been
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reported to have a direct influence on glucose metabolism. Akt expression has been
correlated with increased glycolysis and has been shown to directly promote glucose
uptake without increasing oxygen consumption (Elstrom et al., 2004). These findings
implicate Akt as a possible factor mediating the Warburg effect in cancer which is known
to have a fundamental role in tumorigenesis. This Akt activation may therefore be an
important mechanism involved in enhancing C3 cell growth, especially if in the context
of its activation by low levels of MT1-MMP.
HIF-1 signalling is another important pathway exploited by cancer cells that
contributes to increased cell survival and growth, partly through transcriptional activation
of genes that collectively promote a glycolytic metabolism (Semenza, 2009). MT1-MMP
has been implicated in HIF-1! activation through its interaction with Mint3 and FIH-1 in
cancer cells. This HIF-1! activation in turn promotes cell proliferation through use of a
glycolytic metabolism (Sakamoto et al., 2011). It is possible that high levels of MT1MMP would impair these Mint3 and FIH-1 interactions and subsequently reduce HIF-1!
activation. Thus, cells expressing low levels of MT1-MMP, levels that may optimally
interact with Mint3 and FIH-1, would therefore have an increased ability to utilize the
Warburg effect via HIF-1 signalling, thus contributing to increased growth. Further, the
interaction between MT1-MMP and FIH-1 is dependent on the cytoplasmic tail, which
suggests ΔCD cells would be unable to stabilize HIF-1!, thus impacting proliferation
rate – again reflecting the fact that ΔCD cells cannot transduce signals, such as what was
already seen with their inability to activate ERK signalling. These mechanisms of MT1MMP mediated signalling activation also rely on distinct protein-protein interactions
requiring MT1-MMP to be in the right place, at the right time, to function properly. The
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cytoplasmic tail is directly involved in MT1-MMP localization and internalization and
therefore its deletion would result in the proteins mislocalization disrupting MT1-MMPs
ability to activate various signalling pathways (Jiang et al., 2001; Nakahara et al., 1997).

4.3 All cell lines demonstrate similar proliferative abilities in “sugarfree”, lactate, and pyruvate media
The proliferative advantage of low MT1-MMP levels in C3 cells was not seen
when cells were cultured in media without a carbon source, or supplemented with lactate
or pyruvate, and instead, parental MCF7 cells had greater proliferation in these
conditions, particularly on day 4 and 5 (Figure 4b, c, d). The parental MCF7 cell line has
very low (although not negligible) MT1-MMP expression (Cepeda et al., 2016), and the
enhanced growth of these cells is at odds with the notion that MT1-MMP is involved in
upregulating signalling pathways associated with cell proliferation and survival
(D’Alessio et al., 2008; Sakamoto et al., 2011; Valacca et al., 2015). It is of note that this
proliferative advantage of MCF7 cells around day 4 and 5 is diminished as proliferation
does not differ between all other cell lines by day 6 in “sugar-free”, lactate, and pyruvate
media, indicating this advantage may be short-lived. As cells overexpressing MT1-MMP
(including ΔCD) were neither more proliferative nor more viable than parental MCF7
cells, it is likely MT1-MMP does not play a significant role in modulating cell growth in
the glucose-deprived conditions examined here.
While cells have previously been reported to be able to utilize lactate and
pyruvate via OXPHOS (discussed below), it is possible that our cells may not be
effectively metabolizing these carbon sources as absolute number of cells in media
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containing lactate and pyruvate are comparable to numbers seen in “sugar-free” media
(Figure 4b, c, d). Lactate is known to be toxic in high concentrations (Gatenby et al.,
2007), however, the concentration used in this study (7 mM) was in the normal
concentration range commonly found in various tumour types including breast (Brizel et
al., 2001; Kennedy et al., 2013; Walenta et al., 2000). Additionally, cancer cells
continuously demonstrate the ability to overcome acidic conditions caused by lactate
accumulation that results from upregulated glycolysis (Gatenby et al., 2007). In fact, a
previous study has demonstrated that lactate concentrations ranging from 0-20 mM did
not affect cell viability nor increase cell death responses of MCF7 or MDA-MB-231 cells
in either the presence or absence of glucose. Furthermore, the same study reported that
lactate can be utilized as a legitimate metabolite by cancer cells in vitro and in vivo
(Kennedy et al., 2013). Specifically, MCF7 cells cultured in 20 mM of labelled 13Clactate showed evidence of intracellular lactate accumulation 24 hours after treatment.
Interestingly, when MCF7 cells were cultured in glucose-free media supplemented with
20 mM lactate for 5 days without replenishing media, MCF7 cell number in lactate
showed no differences to MCF7 cells cultured in high-glucose complete media (Kennedy
et al., 2013). This is in stark contrast with the results obtained here (using a similar
protocol) as absolute cell number in lactate media was much lower than that in glucose
for all cell lines (Figure 4a, c). However, it is of note that lactate in this study was
supplemented into media at a concentration of 7 mM, which is lower than the 20 mM
concentration used by Kennedy et al. (2013).
While lactate is commonly associated with the Warburg effect, this association is
due to its accumulation as an end-product of glycolysis, and not as a metabolic substrate.
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Instead, lactate produced from glycolytic cancer cells can be exported and taken up by
oxidative cancer cells to fuel OXPHOS (Sonveaux et al., 2008). Cancer cells cultured in
lactate have shown large increases in oxygen consumption providing evidence that lactate
is metabolized via mitochondrial respiration and not glycolysis (Kennedy et al., 2013).
However, for lactate to be used as an energy source, it must first be converted into
pyruvate, which then feeds into the TCA cycle and subsequent OXPHOS (Kennedy et al.,
2013). For this reason, if cells can use lactate as metabolic fuel, they should similarly be
able to utilize pyruvate. The similarities in growth in lactate and pyruvate are therefore
expected if both metabolites are being used by the cell in the same manner (Figure 4c, d).
However, the discrepancies between MFC7 cell growth in lactate between this study and
results found by Kennedy et al. (2013) are not easily explained. Perhaps 7 mM lactate
supplementation in the media provided insufficient metabolic substrate to support cell
growth compared to media containing concentrations of 20 mM. As the catabolism of
lactate and pyruvate fuel OXPHOS, and thus would not be catabolized via aerobic
glycolysis, it cannot be ruled out that optimal levels of MT1-MMP induce signalling
pathways that promote the Warburg effect ultimately leading to increased growth,
migration, and invasion of C3 cells in glucose. MT1-MMP level or form, however, does
not seem to play a role in mediating cell survival or proliferation of MCF7 cells in
glucose-deprived conditions.
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4.4 Higher MT1-MMP levels may increase anoikis resistance in C1, C3,
and ΔCD cells
When cells become detached from their substrate, typically the ECM, they often
undergo a type of apoptosis termed anoikis. This programmed cell death is a critical
mechanism in place to prevent dysplastic cell growth and re-adhesion to inappropriate
matrices (Taddei et al., 2012). In this study, cells counted in the removed media over
several days revealed cells were still viable even though detached from the plate,
indicating cells may be able to evade or overcome the mechanisms in place that trigger
anoikis. In glucose, detached live cell numbers remained similar and consistent
throughout all 6 days (Figure 5a). While in “sugar-free”, lactate, and pyruvate, detached
live cell number increased after 3 days (Figure 5b, c, d). Additionally, parental MCF7
cells commonly had lower detached live cell numbers compared to cell lines
overexpressing MT1-MMP (with the exception in pyruvate on day 6) despite having
increased adhered cell numbers in their respective treatment. ΔCD cells generally had
higher absolute detached cell number that was almost always greater than MCF7 (except
in pyruvate on day 6) but did not always differ from C1 and C3 (Figure 5 b, c, d).
Overall, cell lines overexpressing MT1-MMP commonly had larger detached live cell
numbers after 3 days than parental MCF7 cells. Indeed, it has been reported that MMP
mediated release from the ECM maybe a key factor used by cancer cells to evade anoikis,
and as such, levels of MMPs are often associated with reduced cancer cell apoptosis
(Wong et al., 2001). Evasion of anoikis is a critical initial step in successful cancer
dissemination, as cells must detach from the basement membrane before entering
circulation and colonizing distant sites. In fact, increased apoptosis of cancer cells has
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been associated with decreased metastasis in vivo, while apoptosis inhibition (via Bcl-2
overexpression) leads to increased microscopic metastases in vivo. Additionally, when
comparing apoptosis between poorly and highly metastatic cell lines, the poorly
metastatic cell lines displayed increased apoptosis. This indicates the ability to evade cell
death upon detachment of the ECM is an important component to cancer progression
(Wong et al., 2001). Studies have linked MT1-MMP specifically in conferring protection
against anoikis in cancer cells. Upon attachment-deprived conditions, MT1-MMP
transfected human hepatocellular carcinoma cells were more viable and maintained
higher metabolic activity compared to the vector control (Ip et al., 2005). This may, in
part, explain why cells overexpressing MT1-MMP commonly had a larger number of
viable detached cells compared to parental MCF7 cells in “sugar-free”, lactate, and
pyruvate media (Figure 5b, c, d).

4.4.1 Anoikis evasion via epithelial to mesenchymal transition
The epithelial to mesenchymal transition (EMT) is a dynamic process whereby
epithelial cells acquire a motile (mesenchymal) phenotype by remodelling cell-cell and
cell-ECM interactions that allow detachment from the underlying basement membrane
(Dongre and Weinberg, 2019). This process occurs during normal embryonic
development, inflammation, and wound healing, however, it can be exploited by cancer
cells leading to metastatic expansion (Roche, 2018). Acquisition of a mesenchymal
phenotype is correlated with anoikis resistance and therefore plays a role in reducing
anoikis sensitivity (Paoli et al., 2013). MMPs are heavily associated with the induction of
EMT specifically via their proteolytic ability to cleave cell-cell junction proteins and cell-
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ECM adhesion proteins (Radisky and Radisky, 2010). For example, MT1-MMP is
capable of processing !v integrin into a functional form resulting in increased migration
of MCF7 cells (Deryugina et al., 2002). Additionally, MT1-MMP can activate MMP-2
and MMP-9 which also function in MMP-induced EMT (Nishida et al., 2008; Radisky
and Radisky, 2010; Toth et al., 2003). While MT1-MMP is not the only MMP involved
in initiating EMT in cancer cells, it certainly has a well-established role in enhancing
cancer cell invasion and metastasis (Egeblad and Werb, 2002); roles that require cell
survival upon ECM detachment thereby demonstrating some degree of anoikis resistance.
Thus, again the presence of MT1-MMP and its role in altering viability may in part
explain the differences in detached cell numbers through this anoikis evasion mechanism.

4.4.2 ΔCD cells commonly have larger absolute detached cell numbers
MCF7 cells transfected with MT1-MMP that has a cytoplasmic domain deletion
(ΔCD cells) have previously been shown to increase migration and invasion compared to
MCF7 cells (Cepeda et al., 2017). Since successful migration and invasion initially
require ECM detachment, this finding by Cepeda et al. (2017) agrees with the elevated
number of live detached ΔCD cells observed here in the absence of glucose (Figure 5).
As an MT1-MMP cytoplasmic domain deletion impairs proper protein localization and
therefore subsequently affects proper proteolytic function (Cepeda et al., 2017), this
indicates the enhanced motility of cells could also be due to non-proteolytic mechanisms.
Several other studies have also indicated that the cytoplasmic domain of MT1-MMP is
not required for the protein to mediate invasion (Hotary et al., 2003; Itoh et al., 2008; Li
et al., 2008). Additionally, proteolytic inhibition of MMP activity in invasive breast
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cancer cells promoted the use of alternative migratory strategies resembling amoeboid
migration which relies on changes in cell morphology that occur independent of ECM
degradation (Wolf et al., 2003). As the cytoplasmic tail is not essential to MT1-MMP
mediated cell migration and invasion, other mechanisms likely supersede its involvement
in modulating cell viability (in adhered cells) when cell-ECM interactions are diminished.

4.4.3 Glucose-deprivation may trigger detachment from substratum
Detached cell numbers in glucose did not increase after day 3, unlike cell numbers
in treated conditions (Figure 5). Glucose-free conditions created a less favourable
environment for cell survival which did not permit the rapid growth and proliferation that
glucose media did. As cancer cells are known to consume enormous amounts of glucose
(Kim and Dang, 2006), glucose media provided cells with a plentiful and an efficiently
metabolized energy source. “Sugar-free”, lactate, and pyruvate, however, created an
environment less permissible to proliferation, growth, as well as promoted the use of
OXPHOS (rather than glycolysis). Therefore, glucose deprivation may elicit numerous
cellular responses as cells adjust to their new environment. One proposed reason behind
the initiation of cancer progression is that cells metastasize to an environment where
nutrients are plentiful, especially as tumours outgrow their surrounding nutrient supply
(Wang et al., 2015). This reasoning provides an explanation as to why live detached
absolute cell numbers are larger in media without glucose – cancer cells survive as they
are forced to potentially change their environments.
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4.5 MT1-MMP has a limited role in modulating metabolic transcript
levels
While the increased growth of C3 cells was abolished in “sugar-free”, lactate, and
pyruvate media, these cells, containing low levels of MT1-MMP, still proliferate faster in
glucose, and show increased migratory and invasive capabilities in vitro and in vivo
(Cepeda et al., 2016). Since each of these characteristics are strongly associated with the
Warburg effect (Epstein et al., 2017; Gatenby and Gillies, 2004; Han et al., 2013; Lu,
2019; Lunt and Vander Heiden, 2011), it was therefore an objective of this study to
identify a potential role of MT1-MMP in mediating metabolic signalling. MCF7 cells
primarily use OXPHOS to generate ATP (Guppy et al., 2002), therefore a metabolic
switch to aerobic glycolysis would likely be reflected by increased expression of
glycolytic genes, and decreased expression of oxidative genes. Initially, 32 metabolic
genes were assessed, from which 10 genes with the largest fold-changes in transcript
levels between cell lines and treatments were selected to be statistically reanalysed. These
genes are ENO2, HIF1!, LDHA, ME1, PCK2, PDK1, PDK3, PDP2, SLC16A1, and
SLC16A3. The implications of differential transcript levels of these key metabolic genes
between b) cell lines and c) metabolites are discussed below.

4.5.1 Functions of the 10 metabolic genes analyzed in this study
Before discussing the role that MT1-MMP may play in the regulation of these
metabolic genes, I will first give an overview of their functions (Figure 8).
ENO2 is a glycolytic enzyme responsible for catalyzing the second last step in
glycolysis to form phosphoenolpyruvate (PEP) before it is then converted into pyruvate
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Figure 8: Illustrative representation of selected metabolic genes and their functions.
ENO2 catalyzes the second last step in glycolysis converting 2-phospho-D-glycerate to
phosphoenolpyruvate (PEP). HIF-1! functions to increase expression of glycolytic genes.
LDHA catalyzes the conversion of pyruvate to lactate. ME1 catalyzes the conversion of
malate to pyruvate. PCK2 catalyzes the conversion of oxaloacetate (OAA) to PEP. PDK1
and PDK3 function to inhibit PDH and prevent the conversion of pyruvate to acetyl-CoA.
PDP2 is responsible for the enzymatic resetting of PDH thereby reactivating the protein.
SLC16A1 and SLC16A3 are both monocarboxylate transporters that transport
monocarboxylates (such as lactate and pyruvate) across the plasma membrane.
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(Liu et al., 2018). Once pyruvate is formed at the end of glycolysis, it can either be
converted into acetyl-CoA via PDH and directed towards mitochondrial respiration or be
converted into lactate via LDHA. Conversion of pyruvate to lactate not only directs
pyruvate away from OXPHOS, but also regenerates NAD+ which is needed for earlier
glycolytic reactions (Feng et al., 2018). The overexpression of both of ENO2 and LDHA
have linked to accelerated glycolysis, increased cell survival, and increased migration in
cancer cells (Feng et al., 2018; Vizin and Kos, 2015).
PDK1 and PDK3 are PDK isoforms that both function to inhibit PDH preventing
flux into OXPHOS thereby promoting glycolysis (Liu and Yin, 2017; Sutendra and
Michelakis, 2013). PDP2 functions in opposition to PDK and relieves PDH inhibition
thereby promoting flux into OXPHOS (Kono et al., 2018). However, when cells rely on
accelerated glycolysis and PDKs are active, pyruvate is converted to lactate, and this
product tends to accumulate. Monocarboxylate transporters SLC16A1 and SLC16A3 are
therefore commonly upregulated to support transport of lactate (and pyruvate if
necessary) across the plasma membrane and are therefore commonly associated with the
hyperglycolytic phenotype of cancer cells (Baltazar et al., 2020; Halestrap, 2013).
ME1 and PCK2, while not directly involved in supporting accelerated glycolysis,
do indirectly contribute to the promotion of glycolysis. ME1 is a gluconeogenic enzyme
catalyzes the conversion of malate (produced in the TCA cycle) to pyruvate, but also
interacts with p53 to promote an increased reliance on aerobic glycolysis (Jiang et al.,
2013; Liao et al., 2018). PCK2 is also a gluconeogenic enzyme that generates the
glycolytic intermediate PEP from oxaloacetate (OAA) which then can feed into and
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support glycolysis (Bluemel et al., 2021; Leithner et al., 2015; Méndez-Lucas et al.,
2014).
Finally, HIF1! is involved in activating transcription of several glycolytic genes
that promote the use of aerobic glycolysis including ENO2 (Leiherer et al., 2014), LDHA
(Masoud and Li, 2015), PDK1 (Liu et al., 2012), PDK3 (Kluza et al., 2012), and
SLC16A3 (Semenza, 2010) which are assessed here. Therefore, not only do these targets
overexpression correlate to increased glycolysis, they also correlate with HIF-1 signalling
as well.

4.5.2 All cell lines display few differences in metabolic transcript levels
in glucose, lactate, and pyruvate media
4.5.2.1 Minimal metabolic transcript level changes in glucose among all
cell lines
In glucose media, where cell lines showed distinct differences in proliferation
(Figure 4), mRNA levels of metabolic genes commonly associated with glycolysis did
not differ between cell lines. Based on the lack of change in levels of the metabolic genes
assessed in this study, C3 cell’s increased proliferation in glucose does not seem to be
attributed to a glycolytic metabolism. While the downregulation of PDK3 in C3 cells in
glucose compared to MCF7 cells suggests the use of an oxidative metabolism is more
prominent (Kluza et al., 2012), this conclusion cannot be made from the differential
expression of just one gene (Figure 6a). Indeed, in contrast to PDK3 downregulation,
PDK3 overexpression has been correlated with increased cancer severity and higher
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recurrence rates due to its critical role in promoting a metabolic shift to glycolysis (Lu et
al., 2011b). As C3 cells are also more migratory and invasive than the other cell lines
(Cepeda et al., 2016), decreased PDK3 mRNA levels were not expected. In highly
glycolytic melanoma cells, inhibition of PDK3 alone was sufficient to restore
mitochondrial respiration which highlights the importance of PDK3 function in
potentiating a glycolytic metabolism (Kluza et al., 2012). Transcriptional regulation of
PDKs in cancer have largely been attributed to aberrant HIF-1 signalling, especially that
of PDK1 and PDK3 (Kluza et al., 2012; Lu et al., 2011b). HIF-1! overexpression has
been seen in many cancers including breast (Zhong. et al., 1999), but its mRNA levels
remained unchanged in C3 cells despite these cells being derived from MCF7 breast
cancer cells that have had their proliferative and invasive capabilities increased –
properties associated with elevated HIF-1 signalling (HIF-1! levels were also unchanged
in other cell lines) (Figure 6a). As HIF-1! levels did not change, it is therefore not
surprising that some of HIF-1’s transcriptional targets (in addition to PDK3) such as
LDHA (Masoud and Li, 2015), PDK1 (Liu et al., 2012), SLC16A3 (Semenza, 2010), and
ENO2 (Leiherer et al., 2014), also do not significantly differ in mRNA levels from
parental MCF7 cells (Figure 6a). It is of note that MT1-MMP mediated HIF-1!
stabilization (and associated changes in metabolism) that has been characterized in cancer
cells occurs via distinct protein-protein interactions and not at the level of altered
transcript levels (Sakamoto et al., 2011). Therefore, even though HIF-1! transcript levels
are unchanged between all cell lines in glucose, this does not conclusively indicate HIF-1
signalling does not differ when MT1-MMP expression or form is manipulated. However,
the unchanged transcript levels of HIF-1 target genes do suggest this signalling pathway
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is not upregulated in any cell line, and that cells are still utilizing OXPHOS, or at
minimum not shifting significantly away from it. However, some of these targets, such as
the PDKs, can also be regulated post-translationally via covalent modifications, allosteric
effectors, and the activity of PDPs. As PDP enzymes function to dephosphorylate PDH
(thereby reactivating the complex), this promotes the conversion of pyruvate to acetylCoA which feeds into the TCA cycle and subsequent OXPHOS (Woolbright et al., 2019).
PDP2 mRNA levels did not differ in any of the cell lines (in any treatment) with respect
to levels in MCF7 cells suggesting PDH reactivation is also not a determining factor
contributing to the observed differences in growth (Figure 6).

4.5.2.2 Minimal metabolic transcript level changes in lactate among all
cell lines
In media containing lactate, it is likely all cell lines are using OXPHOS because
1) lactate has been shown to be metabolized via OXPHOS in cancer cells (Kennedy et al.,
2013) and 2) at the level of gene expression, transcript levels of glycolysis associated
genes ENO2, HIF1!, LDHA, ME1, PDK1, PDK3, and SLC16A1 remain largely
unchanged between cell lines (Figure 6b). Interestingly, ΔCD cells lowered transcript
levels of LDHA and PDK1 compared to parental MCF7 cells whereas other cell lines did
not. Decreases in transcript level of both these metabolic genes further suggest ΔCD cells
are using OXPHOS (Kim et al., 2006; Li et al., 2016), especially since transcript levels
are being compared to that of an already oxidative cell (MCF7). While PDK1 has
different site specificity for PDH phosphorylation than PDK3 (Kato et al., 2007), both
isozymes function to inhibit PDH and their tumorigenic properties are attributed to their
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ability to promote the Warburg effect. Additionally, inhibition of LDHA expression has
been reported to decrease cell malignant transformation and delay tumour formation in
vivo (Fantin et al., 2006). A previous study demonstrated that decreased expression of
LDHA results in reduced cell proliferation, migration, and invasion in vitro,
demonstrating a role for LDHA in cancer progression (Xian et al., 2015). ΔCD cells did
have decreased proliferation compared to MCF7 cells in lactate, however they also had
increased detached cell number (Figure 4, 5). While decreased transcript levels of PDK1
and LDHA may contribute to the slow growth in lactate, these results are contradictory to
the elevated ΔCD cell numbers in the removed media indicating that survival upon
detachment of the substratum in lactate is likely independent of metabolic signalling.

4.5.2.3 Minimal metabolic transcript level changes in pyruvate among
all cell lines
Similar to the lack of differential glycolytic gene expression in lactate and
glucose, cell lines also showed minimal differences from one another in pyruvate.
Transcript levels of glycolysis associated genes ENO2, HIF-1!, LDHA, ME1, PCK2,
PDK3, and SLC16A3 did not differ between cell lines (Figure 6c). As with in lactate
media, ΔCD cells had reduced PDK1 transcript levels in pyruvate implying active PDH
and the conversion of pyruvate to acetyl-CoA for OXPHOS. However, with the lack of
differences between cell lines and transcript levels of glycolysis associated and HIF-1
target genes in all treatments, it is likely that MT1-MMP does not have a role in
mediating cellular metabolism at the level of gene expression.
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4.5.2.4 Transcript levels of monocarboxylate transporters SLC16A1 and
SLC16A3
Special consideration is being made for monocarboxylate transporters as they are
necessary to transport both lactate and pyruvate across the cell membrane (Tauffenberger
et al., 2019). Their overexpression has been associated with the hyperglycolytic
phenotype of cancer cells to accommodate the accumulation of glycolytic end products.
In the proposed metabolic symbiont model, lactate is exported from glycolytic cancer
cells by SLC16A3 only to be taken up by SLC16A1 in oxidative cancer cells and further
oxidized to create ATP (Sonveaux et al., 2008). While SLC16A1 and SLC16A3 are
associated with monocarboxylate uptake and export respectively due to their differential
binding affinities, these transporters are capable of bidirectional transport depending on
the net driving force for lactate (Petersen et al., 2017).
Interestingly, the transcript levels of monocarboxylate transporters SLC16A1 and
SLC16A3 differed in C3 cells compared to MCF7 cells in both lactate and pyruvate, but
were not affected the same way by these metabolites. In lactate, C3 cells had increased
SLC16A3 mRNA levels compared to MCF7, while in pyruvate, C3 cells decreased
SLC16A1 transcript levels (Figure 6 b, c). Due to the increase of SLC16A3 transcript in
C3 cells compared to MCF7 cells in lactate, these cells may have a slightly elevated
ability to transport lactate across the plasma membrane when exogenous lactate is
elevated, however this benefit does not provide any proliferative advantage to cells in this
media (Figure 4c, 6b). On the contrary, C3 cells decreased SLC16A1 transcript levels in
pyruvate suggest a reduced ability to import pyruvate into the cell thereby limiting
potential ATP production. However, monocarboxylate transporter transcript levels in C3
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cells do not differ from either C1 or ΔCD cells. Since C3, C1, and ΔCD cells do not
display any growth difference in pyruvate and only minimal differences in lactate on day
5, differential transcript levels of monocarboxylate transporters are likely not the reason
for C3 cells reduced proliferation in these metabolites (Figure 4c, d, and 5b, c).

4.5.3 All cell lines have similar metabolic transcript levels upon
exposure to lactate and pyruvate
As there was no change in gene levels between cell lines when these cells were
grown in a given metabolite, differences in metabolic transcript levels in response to
lactate and pyruvate were compared to those in glucose within an individual cell line.
These patterns of transcript level changes were shared, increasing, or decreasing similarly
across cell lines, indicating that MT1-MMP likely does not play a significant role in
modulating metabolic gene expression. In fact, the response of MCF7 cells (very low
MT1-MMP levels) and C1 cells (excessive MT1-MMP overexpression) to lactate and
pyruvate were very similar, highlighting that these changes in transcript levels are
probably attributed to the presence of lactate and pyruvate, and not levels of MT1-MMP
(Figure 7a, b).
In all cell lines, ME1 transcript levels were increased in both lactate and pyruvate
(Figure 7). ME1 is a cytosolic enzyme responsible for catalyzing the conversion of
malate to pyruvate while reducing NADP+ to NADPH (Jiang et al., 2013). In breast
cancer, its overexpression has been reported to increase glycolysis and suppress
OXPHOS thereby directly contributing to the Warburg effect and increasing
tumorigenicity of cancer cells (Liao et al., 2018). Since ME1 upregulation is not cell line
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specific, it is likely an adaptive response of the cells to survive under conditions of stress,
in this case glucose-deprivation, and its transcript levels not related to MT1-MMP levels.
Despite such similar responses to lactate and pyruvate, C3 cells were the only cell
line that differed in the transcript levels of HIF-1! (Figure 7c). Aberrant HIF-1 signalling
has a well characterized role in shifting a cells metabolism to glycolysis and its activity is
what has been reported to link MT1-MMP to metabolism (Sakamoto et al., 2011;
Semenza, 2010). However, this HIF-1 signalling requires protein-protein interactions,
specifically with FIH-1 and Mint3, whereby MT1-MMP facilitates FIH-1 inhibition to
activate HIF-1! under normoxic conditions (Sakamoto and Seiki, 2010). Since this
mechanism does not occur at the level of gene expression, MT1-MMP may have
additional roles that work in concert to contribute to normoxic HIF-1 signalling. As
previously discussed, low levels of MT1-MMP may optimally induce not only ERK, but
also Akt signalling; a pathway with known roles in cell survival, proliferation, apoptosis,
motility, and metabolism (Zhang et al., 2018). Akt signalling has been shown to
contribute to HIF-1! overexpression (Zhong et al., 2000; Zundel et al., 2000), underlying
another potential indirect mechanism in which MT1-MMP regulates HIF-1! activity.
Interestingly, LDHA transcript levels are decreased in pyruvate in every cell line
compared to that in glucose, except for C3, which may be due to elevated HIF-1!
transcript. However, other transcript levels of HIF-1 transcriptional targets such as ENO2,
PDK1, PDK3 and SLC16A1 are lowered or remain unchanged (Figure 7c). As elevated
transcript levels of HIF-1! are not accompanied by elevated transcript levels of HIF-1
transcriptional targets, this suggests that elevated HIF-1! in C3 cells may be inhibited by
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PHDs or FIH-1 and therefore unable to dimerize to HIF-1/ and induce transcription of
glycolytic targets.
Of all cell lines, ΔCD had the most transcriptional changes in both lactate and
pyruvate media. In lactate, the decreased transcript levels of ENO2, LDHA, and PDK1,
and the increased transcript levels of PDP2 collectively suggest a more oxidative
metabolism (Feng et al., 2018; Kono et al., 2018; Sutendra and Michelakis, 2013; Vizin
and Kos, 2015), while the increased transcript levels of ME1, PCK2, and SLC16A1 all
suggest a more glycolytic metabolism (Baltazar et al., 2020; Grassian et al., 2011;
Leithner et al., 2015; Liao et al., 2018). Pyruvate media also resulted in similar changes
except that PDP2 and SLC16A1 levels were unchanged, and PDK3 levels were decreased
(Figure 7d). These contradicting changes could suggest a dysregulation of metabolic
signalling pathways or metabolic dysfunction, both of which would be detrimental to the
cell’s energy production, and thus likely contribute to the poor growth of ΔCD cells in
these treatments. However, because ΔCD cells proliferation was similar to C3 and C1
cells, these unrelated changes in metabolic transcript level are likely not the driving force
behind any proliferative differences. The cytoplasmic tail of MT1-MMP is important for
the proteins proper localization within the cell (Cepeda et al., 2017; Lehti et al., 2000;
Uekita et al., 2001), therefore its mislocalization could result in inappropriate interactions
with other bioactive molecules that ultimately induce changes in metabolic gene
expression in an uncoordinated manner. Thus, while ΔCD cells appear to have disrupted
metabolic transcript levels, it is not these changes in metabolism that are critical for
changing cell proliferation. It is likely that MT1-MMPs inappropriate localization and
signalling due to the absence of the cytoplasmic tail in ΔCD cells that are most important
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factors. Indeed, this study demonstrates that while changes in MT1-MMP level or form
can alter a cells proliferation and viability, the mechanism of this change does not appear
to be due to a shift in metabolism, at least not from what can be detected from analyzing
metabolic transcript levels in cells cultured in glucose, “sugar-free”, lactate, and pyruvate
media.

4.6 Study limitations and future directions
This study examined cell growth and transcript levels of several metabolic genes
of MCF7 cells when cultured in glucose, lactate, pyruvate, and “sugar-free” media to
identify differences in MCF7 cells expressing different levels or forms of MT1-MMP.
While the cell lines used in this study (MCF7, C1, C3, ΔCD) have clear proliferative,
migratory, and invasive differences (Cepeda et al., 2016; Cepeda et al., 2017), these
differences are likely not attributed to differential transcript levels of selected metabolic
genes. However, it cannot be ruled out that these cells differ metabolically as many key
regulatory nodes of cell metabolism occur post-translationally such as PDH inactivation
and HIF-1! stabilization (Courtnay et al., 2015; Kiriakidis et al., 2015; Ziello et al.,
2007). Future work should examine metabolic protein level changes to gather a more
well-rounded understanding of metabolic function. Additionally, the bioenergetic state of
the cells lines used in this study should be determined using a Seahorse Bioscience XFe
extracellular flux analyzer which analyzes oxygen consumption rate and extracellular
acidification rate to elucidate the metabolic profile of the cell (Van der Windt et al.,
2016). Together, analyzing metabolic protein level changes and the bioenergetic state of
the cells will provide a more holistic view of the metabolic profile of these cells.
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5. Conclusion
MT1-MMP is a multifunctional enzyme with proteolytic and nonproteolytic roles
that is required during embryogenesis, and that contributes to the promotion and
progression of cancer. While MT1-MMP overexpression has been implicated in cancer
aggressiveness, previous work has demonstrated that low levels of MT1-MMP are
optimal to promote cell proliferation, migration, invasion, and tumour vascularization.
Since these characteristics effectively encapsulate those associated with the Warburg
effect, the aim of this study was to identify if low levels of MT1-MMP optimally
modulate metabolism to meet the cell’s energy requirements, especially during periods of
glucose-deprivation. I hypothesized the slight overexpression of MT1-MMP that
optimizes cell migration, invasion, and viability in C3 cells, also optimizes energy
production. Here, the increased proliferation of C3 cells in glucose was abolished in
media supplemented with either lactate, pyruvate, or without a carbon source which
suggests low levels of MT1-MMP do function to produce this enhanced proliferative
phenotype in glucose. These treatments also all resulted in an increased number of live
cells that were unadhered to the plate which was commonly greater in cell lines
overexpressing MT1-MMP, which highlights a potential role of MT1-MMP in anoikis
resistance. Lastly, MT1-MMP levels or form did not alter metabolic mRNA levels of
selected genes in any treatment demonstrating that proliferative differences of cell lines
cannot be attributed to changes in transcript levels of the metabolic genes examined here
that could indicate a metabolic switch to glycolysis. Overall, this work indicates MT1MMP does not function to increase cell survival or proliferation through modulation of
metabolic transcript levels and that MT1-MMP containing cell’s tumorigenic properties
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may be dependent on the availability of glucose. However, as many changes in metabolic
signalling occur post-translationally, it cannot be ruled out that MT1-MMP expression
may be affecting cell metabolism and/or metabolic signalling cascades that ultimately
promote the Warburg effect independent of metabolic transcript levels to enhance cell
proliferation, migration, and invasion when glucose is abundant.
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Supplementary Information
Supplementary Table 1. Genes included in the initial screen and their respective function
Gene
PDHA1

Name
Pyruvate dehydrogenase
(lipoamide) alpha 1

Related Pathways
Glycolysis
TCA cycle

PDHB

Pyruvate dehydrogenase
(lipoamide) beta
Phosphoenolpyruvate
carboxykinase 1

Glycolysis
TCA cycle
Gluconeogenesis

PCK2

Phosphoenolpyruvate
carboxykinase 2

Gluconeogenesis

PDP2

Pyruvate metabolism
TCA cycle

ENO1

Pyruvate dehydrogenase
phosphatase catalytic
subunit 2
Pyruvate dehydrogenase
phosphatase regulatory
subunit
Phosphoglycerate kinase
1
Enolase 1

ENO2

Enolase 2

PCK1

PDPR
PGK1

Function
• Subunit of pyruvate dehydrogenase
• Converts pyruvate to acetyl-CoA (Korotchkina and Patel,
1995)
• Subunit of pyruvate dehydrogenase
• Converts pyruvate to acetyl-CoA (Seifert et al., 2007)
• Cytoplasmic enzyme
• Converts oxaloacetate to phosphoenolpyruvate (Leithner
et al., 2015)
• Mitochondrial enzyme
• Converts oxaloacetate to phosphoenolpyruvate in the
presence of GTP (Leithner et al., 2015)
• Removes phosphate on PDH thereby activating it
(resetting PDH to its active state) (Kono et al., 2018)

Pyruvate metabolism
TCA cycle

•

Regulatory subunit of PDP (Guo et al., 2020)

Glycolysis

•

Glycolysis

•

Glycolysis

•

Catalyzes the first ATP producing reaction in glycolysis
(Nie et al., 2020)
Converts 2-phosphoglycerate to phosphoenolpyruvate in
glycolysis (Huang et al., 2018)
Catalyzes the conversion of 2-phospho-D-glycerate to
phosphoenolpyruvate (PEP); the second last step in
glycolysis (Liu et al., 2018)
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HK2

Hexokinase 2

Glycolysis

•

PDK1

Pyruvate dehydrogenase
kinase 1

Glycolysis
TCA cycle

•
•
•

PDK2

Pyruvate dehydrogenase
kinase 2
Pyruvate dehydrogenase
kinase 3
Pyruvate dehydrogenase
kinase 4
Succinate-CoA ligase
GDP-forming beta
subunit
Oxoglutarate
dehydrogenase

Glycolysis
TCA cycle
Glycolysis
TCA cycle
Glycolysis
TCA cycle
TCA cycle

•
•
•
•
•
•
•

TCA cycle

•

Pentose phosphate
pathway
Glycolysis

•

GCK

Glucose-6-phosphate
dehydrogenase
Glucokinase

ACLY

ATP citrate lyase

Fatty acid biosynthesis

•

SDHC

Succinate
dehydrogenase

Pyruvate metabolism
TCA cycle

•

PDK3
PDK4
SUCLG2
OGDH
G6PD

•
•
•

Catalyzes the first step in the glycolytic pathway;
converting glucose to glucose-6-phosphate (Nawaz et al.,
2018)
PDK isoform
Phosphorylates PDH thereby inactivating it
Prevents conversion of pyruvate to acetyl-CoA (Liu and
Yin, 2017)
PDK isoform
See PDK1 description for function
PDK isoform
See PDK1 description for function
PDK isoform
See PDK1 description for function
Couples the hydrolysis of succinyl-CoA to the synthesis
of GTP in the TCA cycle (Miller et al., 2011)
Catalyzes the conversion of alpha-ketoglutarate to
succinyl-CoA and CO2 in the TCA cycle (Armstrong et
al., 2014)
Functions to provide reducing power in the form of
NADPH (Wang et al., 2014)
Member of the hexokinase family of proteins
Phosphorylates glucose to produce glucose-6-phosphate
Unlike other hexokinases, GCK is not inhibited by its
product (Sternisha and Miller, 2019)
Responsible for the synthesis of cytosolic acetyl-CoA
(Lord et al., 1997)
Also known as mitochondrial complex II
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Oxidative
phosphorylation

•
•

MDH1

Malate dehydrogenase 1

TCA cycle
Malate-aspartate shuttle

•
•

LDHA

Lactate dehydrogenase
A
Lactate dehydrogenase
B
Hypoxia inducible factor
1 alpha

Glycolysis

•
•
•

SLC16A1

Solute carrier family 16
member 1

Glycolysis

•
•
•

SLC16A3

Solute carrier family 16
member 3

Glycolysis

•
•
•

ME1

Malic enzyme

Glycolysis

GPI

Glucose-6-phosphate
isomerase

Glycolysis

•
•
•

18S

18S ribosomal RNA

Translation

•

LDHB
HIF1A

Gluconeogenesis
Oxidative metabolism
Hypoxia signalling
Glycolysis

•
•

Couples the oxidation of succinate to fumarate in TCA
cycle
Responsible for reduction of ubiquinone to ubiquinol in
the electron transport chain (MacFarlane et al., 2020)
Catalyzes oxidation of malate to oxaloacetate
Important reaction for NADH supply for oxidative
phosphorylation (Broeks et al., 2019)
Converts pyruvate to lactate
Regenerates NAD+ (Feng et al., 2018)
Predominantly converts pyruvate to lactate (Chen et al.,
2016)
Oxygen regulated subunit of the HIF-1 transcription factor
Transcriptional targets function to promote glycolysis,
angiogenesis, survival, proliferation, and metastasis
(Ziello et al., 2007)
Also known as monocarboxylate transporter 1 (MCT1)
Associated with glycolytic phenotype
Responsible for the uptake/export of lactate across the
plasma membrane (Baltazar et al., 2020)
Also known as monocarboxylate transporter 4 (MCT4)
Associated with glycolytic phenotype
Responsible primarily for the export of lactate across the
plasma membrane (Baltazar et al., 2020)
Catalyzes the conversion of malate to pyruvate
Dependent on NADP+ (Liao et al., 2018)
Catalyzes the conversion of glucose-6-phosphate to
fructose-6-phosphate in the second step of glycolysis
(Mojzikova et al., 2018)
Part of ribosomal RNA
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•
ACTB

Actin beta

Cytoskeletal network

•

TFRC

Transferrin receptor

Iron transport

•
•

GUSB

Glucuronidase beta

Glycosaminoglycan
metabolism
Innate immune system

•

Responsible for converting mRNA to chains of amino
acids (Lafontaine and Tollervey, 2001)
Conserved cytoskeleton structural component (Gu et al.,
2021)
Responsible for the uptake of transferrin-bound iron
Involved in regulating intracellular iron transport
(Fillebeen et al., 2019)
Involved in the breakdown of glycosaminoglycans (Naz et
al., 2013)
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Supplementary Table 2. Transcript level fold-change between cell lines within an individual metabolite relative to MCF7 cells.
G-MCF7
L-MCF7
P-MCF7
Gene
G-C1
G-C3
G-ΔCD
L-C1
L-C3
L-ΔCD
P-C1
P-C3
P-ΔCD
ENO2
5.349
3.981
9.444
5.865
1.683
0.664
1.804
1.770
0.964
0.891
0.400
0.697
0.568
0.232
0.343
1.114
1.212
1.004
HIF1!
LDHA
1.982
1.073
1.817
4.702
0.580
0.206*
1.372
1.925
0.718
ME1
1.682
1.437
2.733
0.799
0.583
0.852
0.992
1.121
0.900
PCK2
1.470
1.173
0.788
0.781
1.977
3.097
1.045
1.091
0.640
PDK1
0.584
0.382
0.818
0.764
0.934
0.390*
0.738
0.628
0.319*
PDK3
0.841
0.253**
0.534
0.495
0.649
0.748
0.963
0.591
0.786
PDP2
1.051
0.649
0.970
0.393
0.845
1.341
0.863
1.197
1.200
SLC16A1
0.352
0.268
0.314
0.400
0.496
1.674
0.360
0.244*
0.326
SLC16A3
2.407
3.331
3.795
2.920
5.229*
3.455
1.548
2.544
1.508
**, p<0.01; *, p<0.05
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Supplementary Table 3. Transcript level fold-change between metabolites within an individual cell line relative to that cell line
cultured in glucose.
G-MCF7
G-C1
G-C3
G-ΔCD
Gene
L-MCF7
P-MCF7
L-C1
P-C1
L-C3
P-C3
L-ΔCD
P-ΔCD
ENO2
1.955
0.714
2.086
0.234
0.896
0.343
0.195*
0.103**
5.179
2.363
2.930
2.726
2.803
6.943*
2.389
3.321
HIF1!
LDHA
1.701
0.270*
3.751
0.179*
0.808
0.438
0.176**
0.101***
ME1
21.078**** 9.901****
8.926***
6.220***
7.858***
8.481***
5.793**
3.436*
PCK2
2.869
5.014**
1.453
3.615
5.351**
5.489**
10.609***
4.078*
PDK1
0.649
0.418
0.851
0.539
1.597
0.704
0.350**
0.188***
PDK3
0.351*
0.183****
0.236***
0.231***
0.934
0.428*
0.566
0.299*
PDP2
4.652
2.409
1.126
2.230
3.633
4.641*
4.899*
3.956
SLC16A1
0.959
0.968
1.074
1.011
1.632
0.840
5.640**
1.149
SLC16A3
1.167
0.584
0.520
0.404
0.614
0.439
0.361
0.231
****, p<0.0001; ***, p<0.001; **, p<0.01; *, p<0.05
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Supplementary Table 4. Average transcript Ct values.
Glucose
Gene
MCF7
C1
C3
ΔCD
MCF7
ENO2
31.349 25.926 24.173 24.668 35.879
26.969 24.126 23.362 23.581 29.020
HIF1!
LDHA
24.510 20.597 19.410 19.720 28.183
ME1
31.462 27.839 26.120 26.144 31.618
PCK2
28.928 25.762 24.216 25.227 31.694
PDK1
28.376 26.530 25.061 24.802 33.202
PDK3
26.758 24.505 24.012 23.753 32.401
PDP2
32.928 30.367 28.866 29.303 35.677
SLC16A1 26.395 25.198 24.785 24.580 31.176
SLC16A3 29.816 26.006 24.699 24.292 36.496

Lactate
C1
C3
33.250 29.057
30.728 26.390
27.708 24.161
32.497 27.497
31.657 25.951
32.947 28.499
32.783 28.241
36.395 31.103
32.159 27.772
34.558 29.075

ΔCD
32.105
27.040
26.993
28.306
27.432
31.997
30.091
32.702
27.103
31.316

MCF7
31.068
25.027
25.728
27.383
26.048
29.059
28.639
31.073
26.231
30.464

Pyruvate
C1
C3
29.642 27.856
24.074 22.709
24.259 22.403
26.335 24.833
25.488 23.813
28.911 27.714
27.986 27.271
30.636 28.884
27.184 27.100
29.543 27.622

ΔCD
29.798
23.597
24.686
26.183
26.068
30.062
28.323
30.175
27.600
29.671
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